Aoki v. Gilbert

• Court: District Court, E.D. California
• Decided: November 17, 2020
• Docket: 2:11-cv-02797
• Status: Unknown

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 EASTERN DISTRICT OF CALIFORNIA 10 11 THOMAS T. AOKI, M.D.; AOKI No. 2:11-cv-02797-TLN-CKD DIABETES RESEARCH INSTITUTE, a 12 California Non-Profit Corporation, 13 Plaintiff, FINDINGS OF FACT AND CONCLUSIONS OF LAW 14 v. 15 GREGORY FORD GILBERT; BIONICA INC., a Nevada Corporation; et al., 16 Defendants. 17

18 19 On October 24, 2011, Plaintiffs Thomas T. Aoki, M.D. (“Dr. Aoki”), and Aoki Diabetes 20 Research Institute (“ADRI”) (collectively, “Plaintiffs”) initiated the above-captioned action. 21 (ECF No. 1.) On April 2, 2013, Plaintiffs filed a First Amended Complaint asserting, inter alia, 22 causes of action for patent infringement, copyright infringement, false and misleading advertising 23 under federal and California law, and unfair competition under federal and California law against 24 numerous defendants, of which the following remain (“Defendants”): Gregory Ford Gilbert; 25 Bionica Inc. (“Bionica”); Bionica Int’l, LLC1; Trina Health, LLC (“Trina” or “Trina Health”); 26 1 The FAC names Bionica Int.’l, LLC, a California limited liability company. (ECF No. 27 135.) At trial, it was revealed that the LLC converted to a general partnership and the parties agreed to substitute Bionica International (a general partnership) in place of the former LLC. (RT 28 Vol. 1 at 63:8–71:20; 73:6–10.) The complaint has not been amended to reflect Bionica 1 Trina Health of Newport Beach, LLC; MedEdCo, LLC; Diabetic Innovations, LLC; Melanie J. 2 Kunz; Michael R. McCarthy; Marc R. Rose, M.D.; Kevin J. Buckman, M.D.; Timothy Tight; 3 Faising S. Chui; Diabetic Life Pulse of Louisiana, LLC2; Limi Management, Inc.; Diabetic Life 4 Pulse, Inc.3; Life Pulse Health, LLC4; John D. Mullen; Glenn A. Wilson; and Richard L. Girard. 5 The FAC additionally asserts causes of action for breach of fiduciary duty and breach of 6 confidential relationship against Defendant Gilbert only. (ECF No. 135.) 7 The Court will not recount the very lengthy procedural history of this case leading up to 8 trial. The Court conducted a nineteen-day bench trial, beginning March 25, 2019, and concluding 9 June 13, 2019. Put most succinctly, at trial Plaintiffs contended Defendants infringed Dr. Aoki’s 10 patents for his pulsed insulin diabetes treatment method5; infringed Dr. Aoki’s copyrighted slides; 11 and made false or misleading statements amounting to false advertising and unfair business 12 practices. Plaintiffs additionally asserted that Mr. Gilbert breached a fiduciary duty to and 13 confidential relationship with Plaintiffs by using confidential information received as both an 14 attorney for Plaintiffs and officer, director, or board member of certain Aoki-owned entities in a 15 manner adverse to those entities. Defendants defenses consisted of the following: (1) the patents 16 are invalid due to obviousness and public use; (2) Defendants’ treatment did not infringe Dr.

17 International (GP), nor was evidence submitted confirming the change in corporate status. As 18 such, the Court addresses only Bionica Int.’l, LLC — which has a suspended corporate status per the California Secretary of State website of which the Court takes judicial notice — herein. 19 2 Diabetic Life Pulse of Louisiana, LLC, has a revoked corporate status in Louisiana. See 20 https://coraweb.sos.la.gov/commercialsearch/CommercialSearchDetails.aspx?CharterID=985777 _CE7614B860. 21

22 3 At the time of trial, Diabetic Life Pulse, Inc. had a suspended or forfeited status. By way of a motion in limine Plaintiffs sought a default judgment. At that time, the Court indicated it 23 would enter such a judgment pursuant to relevant case law if and when judgment was entered in this case. (RT Vol. 1 at 60:7–72:9.) 24 25 4 Life Pulse Health, LLC also had a suspended or forfeited status at the time of trial. (RT Vol. 1 at 60:7–72:9.) 26 5 Dr. Aoki’s patents at issue in this litigation, as set forth below, are collectively referred to 27 as the “RQ patents.” Along with the ‘810 patent (also described below), the RQ patents set forth a pulsatile insulin treatment protocol that came to be termed MAT. Mr. Gilbert and his related 28 clinics/entities term their treatment APT. The Court will use those names herein. 1 Aoki’s patents; (3) the slides are not copyrightable; (4) Defendants’ use of the slides constitutes 2 fair use; (5) Defendants made no false statements and engaged in no false advertising; and (6) 3 Defendants did not engage in unfair business practices. Additionally, Mr. Gilbert claims he 4 and/or Trina have a license to use Dr. Aoki’s treatment protocol. 5 On August 5, 2019, Plaintiffs submitted proposed findings of fact and conclusions of law. 6 (ECF No. 430.) The Trina Defendants6 filed the same on August 6, 2019 (ECF No. 431), and Mr. 7 Gilbert filed a supplemental document the same day, indicating he joined in the Trina 8 Defendants’ proposed findings of fact and conclusions of law and adding additional proposed 9 findings of fact (ECF No. 432). 10 Having considered the evidence presented at trial and the parties' proposed findings of fact 11 and conclusions of law submitted after trial, the Court sets forth the following findings of fact and 12 conclusions of law, in accordance with Federal Rule of Civil Procedure 52(a).7 13 I. FINDINGS OF FACT 14 Mr. Gilbert’s Credibility 15 1. Based on his testimony as a witness as well as representations made in his role as 16 counsel, the Court finds Mr. Gilbert not credible. Mr. Gilbert’s credibility is undermined by 17 repeated statements he made during trial that were contradicted by his own subsequent 18 statements, his own prior statements, or by witness testimony and other evidence the Court finds 19 more credible than Mr. Gilbert’s contradictory evidence. The Court has therefore chosen to 20 disregard many of Mr. Gilbert’s statements in favor of the contradictory testimony of either Dr. 21 Aoki or other witnesses.8 22

23 6 The “Trina Defendants” are all Defendants excluding Mr. Gilbert.

24 7 Any finding of fact that may be construed as a conclusion of law is hereby also adopted as a conclusion of law. Likewise, any conclusion of law that may be construed as a finding of fact is 25 hereby also adopted as a finding of fact. See, e.g., ProMex, LLC v. Hernandez, 781 F.Supp.2d 1013, 1016, 1019 (C.D. Cal. 2011). 26

27 8 The Court provides examples of Mr. Gilbert’s contradictory statements below. These examples are not an exhaustive list. Indeed, many of the Court’s findings of fact may be 28 contradicted by Mr. Gilbert’s testimony. Unless otherwise noted, the Court has disregarded that 1 2. The Court notes the magistrate judge assigned to the action issued discovery 2 sanctions against Mr. Gilbert in the amount of $10,355, finding Mr. Gilbert’s failure to produce 3 documents and comply with discovery orders to be “unacceptable” and “his excuses 4 disingenuous.” (ECF No. 271.) The order also found Mr. Gilbert’s excuses regarding an email 5 relating to discovery issues to be a “false representation to the court.” (Id.) 6 3. Mr. Gilbert represented “we don’t have investors . . . [w]e don’t have anything to 7 do with investors.” (RT Vol. 5 at 690:12–14.) However, Matt Kalifeh, an investor, testified that 8 Mr. Gilbert informed him he was the one who wrote the investor prospectus for investment in a 9 Trina Health clinic in Alabama. (RT Vol. 5 at 791:7–9; 841:15–23; PX 112.) Additionally, Mr. 10 Gilbert later testified that he would approach “finders or fund seekers” or they would approach 11 him. (RT Vol. 12 at 2046:14–18.) 12 4. Mr. Gilbert objected to admission of an exhibit on grounds that Trina West LA “is 13 not part of Trina. It’s an independent company. And there’s nothing foundationally that has to 14 do with this case.” (RT Vol. 9 at 1182:22–24.) Later, Mr. Gilbert stated that Defendants “will 15 stipulate that Trina Health . . . licensed West LA.” (Id. at 1490:8–9.) 16 5. There was extensive testimony about www.diabetes.net, a web site on which many 17 of the clinics licensed by Trina Health posted their site’s text. At trial, Mr. Gilbert repeatedly 18 claimed he was not the owner or registrant for www.diabetes.net. (RT Vol. 9 at 1455:8–10; RT 19 Vol. 11 at 1918:11–12; 1925:17–18.) When pressed on the issue, however, Mr. Gilbert stated he 20 “registered it” but didn’t “register it for [him]self” and that he “registered for Biophile.” (RT Vol. 21 11 at 1918:13–16; see also id. at 1919:12–15.) He also acknowledged he has had the right “for a 22 long time” to control what goes on www.diabetes.net (id. at 1920:17–20), and that he allowed 23 people to put content on diabetes.net (id. at 1929:18–21). 24 6. Additionally, the 2015 Trina Prospectus states that “[e]ach clinic will have its own 25 web site [sic], and will also rely upon diabetes.net for much of the marketing of APT. The 26 website, www.Diabetes.net will help educate the public, including medical professionals and 27

28 testimony because it finds Mr. Gilbert to be not credible. 1 prospective patients, on the benefits of APT.” (PX 112 at Bates 4611.) 2 7. The Court finds Mr. Gilbert’s distinction between registering www.diabetes.net, 3 being the registrant of www.diabetes.net, and owning and/or controlling the content on 4 www.diabetes.net to be disingenuous at best. Indeed, Mr. Gilbert’s testimony surrounding the 5 website was generally confusing and misleading. (See, e.g., RT Vol. 11 at 1921:10–24.) This is 6 particularly true given the fact that Mr. Gilbert as counsel participated in several arguments about 7 whether various clinic websites taken from www.diabetes.net should be received in evidence as 8 showing the overall advertising and control scheme of the Trina entities. In this context, the 9 Court concludes that Mr. Gilbert was not being honest with the Court as to the provenance or 10 purpose of the various clinic sites appearing on www.diabetes.net. 11 8. Mr. Gilbert acknowledged he was a lawyer for ADRI, but testified he was never 12 Dr. Aoki’s counsel. (RT Vol. 10 at 1784:16–18; RT Vol. 11 at 2074:12–2075:7.) The Court 13 finds these representations not credible as the documentary evidence reflects otherwise. (PX 61 14 (stating Dr. Aoki “has personally been my client for many, many years”); PX 25 (letter on “Law 15 Offices of Gregory F. Gilbert” letterhead stating that Mr. Gilbert has acted as counsel for “Aoki 16 in connection with the transactions contemplated by the [AMSys] Agreement”); PX 26 (AMSys 17 Corporation Closing Memorandum in which Mr. Gilbert represented himself as Dr. Aoki’s 18 attorney).) 19 9. During trial, Mr. Gilbert perpetually attempted to disclaim any connection with 20 various website documents, even where the documents contained the APT logo with the “man” 21 symbol that he trademarked. Mr. Gilbert testified that the APT description had to be 22 accompanied by the “little man” logo. (RT Vol. 11 at 1947:1–4.) Later, when he was questioned 23 regarding other documents containing the APT sign with the “man logo,” he testified that the logo 24 also had to have a “zero R” on it. As the Court acknowledged, “[T]he bar kind of keeps on 25 moving. Earlier you never said that.” (RT Vol. 11 at 1950:22–1951:17.) 26 Dr. Aoki’s Credentials and Credibility; Early Development of Technology 27 10. Dr. Aoki testified at length about his background as it pertained to the eventual 28 patents at issue in this litigation. The Court finds Dr. Aoki to be a credible witness and briefly 1 summarizes that testimony here. 2 11. Dr. Aoki received his medical degree from Yale Medical School. (PX 9.) From 3 1966 to 1968, he went to Japan to study the residual effects of the atomic bomb explosion in 4 Hiroshima and Nagasaki, which prompted his interest in endocrinology, and specifically diabetes. 5 (RT Vol. 1 at 81:6–23.) In 1969, Dr. Aoki joined the Joslin Diabetes Center, where he studied 6 starvation metabolism and researched body tissues (i.e. liver, pancreas, kidneys) to understand 7 what happens when a person is starving. As a result, he discovered that the liver was the key to 8 the process of metabolism. (Id. at 85:10–89:4.) 9 12. In 1978, Dr. Aoki got an artificial pancreas machine, the Biostator, which could 10 safely give insulin intravenously by constantly monitoring the glucose level and could 11 automatically stop giving insulin and start giving glucose to avoid hypoglycemia. The machine 12 was intended to control the patient’s blood glucose level. Dr. Aoki spoke with the inventor of the 13 machine, Tom Clemens, and explained his idea of giving large amounts of insulin intravenously 14 for days with the primary purpose not of controlling the blood glucose level but to biochemically 15 turn on the liver cells. (RT Vol. 1 at 107:1–109:13.) 16 13. In 1982, Dr. Aoki published the Foss paper in the Journal of Diabetes, a study on 17 using an (unmodified) Biostator to give square waves of insulin in response to any rise in glucose 18 levels. The Foss paper demonstrated that by giving these square waves, the Biostator could “turn 19 the liver on.” Dr. Aoki’s desire to do it quicker and more efficiently gave birth to the ‘810 patent. 20 Dr. Aoki testified that at that time, the goal was to improve glucose control. He testified that 21 good glucose control was associated with slowing the progression of retinopathy, neuropathy, 22 kidneys, and wound healing. (RT Vol. 1 at 117:22–118:15.) 23 14. The ‘810 patent was filed in 1983, issued in 1989. (RT Vol. 1 at 121:15; PX 1.) 24 15. In 1984, Dr. Aoki moved to Sacramento to become Chief of the Division of 25 Endocrinology and Professor of Medicine at UC Davis. (RT Vol. 1 at 128:11–12.) 26 16. In the course of conducting research on turning the liver back on, Dr. Aoki 27 conceived of the idea of measuring the production of CO2 to O2 consumed before and after 28 exposing diabetic patients to his procedure. The respiratory quotient (“RQ”) was the measure of 1 CO2 produced to O2 consumed. Dr. Aoki testified that an increase in the ratio of CO2 produced 2 to O2 consumed (i.e. “RQ”) would indicate that the diabetic patient’s liver cells were (1) taking 3 up the ingested glucose and (2) “burning” or oxidizing it. (RT Vol. 1 at 152:3–153:24.) 4 17. In the late 1990s, Dr. Aoki noticed that in some patients, glucose control worsened 5 but the complications they were studying, like eyes and kidneys, stayed stabilized. At that time, 6 Dr. Aoki had not settled on final adjustments for measuring RQ, nor had he determined how to 7 modify the treatment if he was looking for other physiological results outside of glucose control. 8 His focus was on glucose control and using the RQ as an indicator of liver function. (RT Vol. 1 9 at 157:3–160:17.) 10 18. At some point after 1999, Dr. Aoki decided to do a baseline RQ and then 11 aggressively and rapidly increase, by increasing the size of the insulin pulses, the RQ response so 12 that within an hour the RQ had exceeded .9 and remained elevated at one, two, and three hours of 13 the procedure to insure that the metabolic milieus of the new target tissues (i.e. eye, kidney) were 14 also biochemically enhanced like that of the liver. He also increased the frequency of treatment 15 days from once a week to 2–3 times per week as appropriate. And he began looking specifically 16 to see if the complications were responding to these changes, i.e. was the kidney more stable than 17 before in response to this more aggressive implementation of a different protocol, and he found 18 they were. (RT Vol. 1 at 165:8–167:4.) Unlike the original ‘810 patent, the higher insulin and 19 glucose doses reflected in the RQ patents recognize these higher doses are needed to treat diabetic 20 complications. (Id.; RT Vol. 18 at 3004:13–23.) 21 Relevant Transactions 22 19. As part of Dr. Aoki’s recruitment package to UC Davis, he could form the 23 equivalent of a “Joslin West”: a nonprofit to be set up by Dr. Aoki and presumably affiliated with 24 the university where he could continue his research. Dr. Aoki was referred to Mr. Gilbert who 25 had a diabetic daughter, to help him set up this Joslin West. Subsequently, Dr. Aoki met with Mr. 26 Gilbert and he ultimately agreed to set up the non-profit, Aoki Diabetes Research Institute 27 (“ADRI”) free of charge, with the hope that Dr. Aoki’s treatment would benefit his daughter. In 28 January 1986, ADRI was incorporated in California. (RT Vol. 1 at 147:9 – 149:10.) 1 20. As part of his work with Dr. Aoki, Mr. Gilbert drafted and voluntarily executed on 2 February 3, 1986, a confidentiality agreement agreeing to assign any inventions/improvements, to 3 Dr. Aoki made or conceived by him during the time that he worked with Dr. Aoki. (PX 245; RT 4 Vol. 17 at 2726:1–2727:25.) 5 21. On or around 1987, AMSys invested $1 million in ADRI to facilitate continuing 6 research. In return, Dr. Aoki licensed his technology to AMSys, which at the time consisted of 7 just the ‘810 patent. (RT Vol. 1 at 177:16– 22; 183:8–23.) 8 22. By 1993, AMSys was running out of money. AMSys and Connecticut Innovations 9 (“CI”9) — a state agency that provides companies with start-up funds — entered into a 10 development agreement whereby AMSys received $1 million dollars from CI, and if AMSys 11 defaulted on the repayment, CI would receive a nonexclusive license and right to sublicense the 12 therapy. Dr. Aoki testified that CI could not sell that “default license” without his written 13 consent. (PX 30 (AMSys-CI License); RT Vol. 1 at 184:5–186:9.) 14 23. Before the development agreement could happen, the 1987 AMSys-Aoki license 15 was clarified to separate out Asia from the license and modified to allow AMSys to offer a 16 potential license or sublicense to CI, in the event of a default. (PX 28 (Clarification License); RT 17 Vol. 2 at 200:12–25; PX 29 (Modification License); RT Vol. 2 at 201:12–22.) Pursuant to the 18 Modification of License Agreement between AMSys and Dr. Aoki, AMSys should notify Dr. 19 Aoki of any default of the development agreement. (PX 29.) 20 24. Mr. Gilbert was the lawyer Dr. Aoki worked with in connection with the AMSys- 21 Aoki and AMSys-CI licenses. Mr. Gilbert reviewed and/or created these licenses. Dr. Aoki 22 understood Mr. Gilbert was working as an attorney for both Dr. Aoki and AMSys in connection 23 with the AMSys-Aoki and AMSys-CI transactions. Although Baker-McKenzie largely prepared 24 the AMSys-Aoki license, Mr. Gilbert reviewed the entirety of this license with Dr. Aoki and then- 25 CEO of AMSys, Joe Marin. Dr. Aoki worked only with Mr. Gilbert in preparing the AMSys-CI 26

27 9 Connecticut Innovations, Incorporated is sometimes referred to in the record as “CII.” For clarification, the Court will refer to simply “CI,” understanding this is the same entity. 28 1 license. (RT Vol. 2 at 201:19–203:4.) 2 25. Subsequently, Mr. Gilbert identified another group of individuals who owned a 3 corporation called Diabetex interested in purchasing Dr. Aoki’s technology to commercialize it 4 by setting up clinics and collecting reimbursement from health insurance companies. Mr. Gilbert 5 advised on the mechanism for the sale of assets from AMSys to Diabetex via another created 6 entity, AMTech. (RT Vol. 2 at 206:25–209:11; PX 36 (Diabetex Agreement and Plan of Reorg).) 7 26. Diabetex got its license in 1999. By 2001, Diabetex ran out of money to 8 commercialize the technology, had stopped providing the promised funds for patents and 9 research, and as a result was in breach of the agreement. Mr. Gilbert led the process of 10 terminating Diabetex’s agreement. Ultimately Diabetex agreed to relinquish Dr. Aoki’s 11 technology in exchange for return of Dr. Aoki’s and others’ shares of Diabetex and $150K. (RT 12 Vol. 2 at 214:22–218:4; 223:17–20; PX 40 (7-16-01 meeting minutes); PX 41 (8-08-01 meeting 13 minutes); PX 43 (9-17-01 meeting minutes).) 14 27. Phil Gurian (not Mr. Gilbert) ultimately paid the $150,000 that went to Diabetex to 15 accomplish the settlement. (PX 46; PX 63 (Nevada Evid. Hearing Tr.) at 39-41; 115-116; RT Vol. 16 8 at 1368:20–24.) 17 28. On August 28, 2001, the return of Dr. Aoki’s technology was accomplished. (PX 18 42.) Although the settlement agreement provides for the return of Dr. Aoki’s technology to Mr. 19 Gilbert, Dr. Aoki was informed by Mr. Gilbert, who was acting as his personal lawyer, that he 20 was simply acting as the agent for PAT. (RT Vol. 2 at 227:23–229:10.) 21 29. On June 7, 2004, Mr. Gilbert testified in the Nevada action that after the Diabetex 22 rights were terminated, they came back to Dr. Aoki personally and that Dr. Aoki “had everything, 23 not only the licenses rights, he had the control. He had everything.” (PX 63 at 39:1–10; see also 24 RT Vol 12 at 2096:13–2100:25; PX 63 at 76–77.) 25 30. Also, in 2001 Dr. Aoki licensed the subject technology to Pulse Activation 26 Therapies (“PAT”), which would later become Metabolic Industries (“MI”). (PX 39 (Aoki-PAT 27 License Agreement); PX 47 (Aoki-MAT License Agreement).) 28 31. The Aoki-MI agreement is signed by Dr. Aoki individually and Mr. Gilbert as 1 president of MI, indicating Mr. Gilbert acknowledged that the rights to the technology went back 2 to Dr. Aoki following the Diabetex settlement, which rights Dr. Aoki then licensed to MI. (PX 3 47.) 4 32. On March 29, 2002, MI entered into a management services agreement with 5 Advanced Diabetes Treatment Centers of Florida (“ADTC”) for purposes of starting clinics and 6 developing locations for providing Dr. Aoki’s MAT treatment. The agreement is signed by Mr. 7 Gilbert on behalf of MI. (PX 55.) 8 33. On July 17, 2002, ADTC, Dr. Aoki, and Hamilton-May (d/b/a Bionica, Inc.) 9 entered into an agreement assuring ADTC that in the event MI couldn’t perform under its 10 management service agreement with ADTC, Dr. Aoki would continue to license his technology to 11 ADTC. This agreement recites that Dr. Aoki designed, developed, and tested MAT and that Dr. 12 Aoki is the owner of all patent rights that pertain to MAT. (PX 57, ¶¶ A, B.) This agreement is 13 signed by Mr. Gilbert on behalf of Hamilton-May. 14 34. On January 24, 2002, the Resolution of Advanced Metabolic Technologies, Inc. 15 (“AMTech”) Debt Agreement was executed by Mr. Gilbert as CEO of MI acknowledging MI is 16 the “new licensee from Thomas T. Aoki, M.D. of those patents and technology related to the 17 procedure known as ‘Hepatic Activation,’ ‘Chronic Intermittent Intravenous Insulin Therapy,’ 18 and ‘Pulsatile Intravenous Insulin’. . . .” (PX 52.) 19 35. Up to the execution of the Diabetex settlement agreement, Dr. Aoki never 20 discussed with Mr. Gilbert nor did he have any discussions with any members of the board of 21 directors of what was then PAT of Mr. Gilbert personally receiving any part of the intellectual 22 property that Diabetex was releasing. (RT Vol. 2 at 226:5–17.) 23 36. The Court finds Mr. Gilbert’s present claim that certain patent rights transferred to 24 him via the Diabetex settlement is not credible.10 25 Bionica Transactions 26 37. Originally, Dr. Aoki gave insulin pulses using a reverse-engineered Biostator, then 27 10 This is consistent with what the Court understands to be the outcome of the Nevada 28 litigation. 1 he used the much simpler AccuPro pump combined with an Epson computer, and thereafter the 2 Bionica pump. The Bionica pump was discovered when Dr. Aoki sent Mr. Gilbert to a trade 3 show in southern California and he met Vladimir Feingold, the president and owner of an 4 Australian company called Bionica, who had invented an analgesia pump which intravenously 5 infuses painkilling meds. The pump was approved for analgesia use, but that certification was 6 insufficient for infusing insulin. Dr. Aoki then met with Feingold at UC Davis and told him what 7 he needed, which was to use the same programming as the AccuPro and Epson computer device. 8 Dr. Aoki along with Mr. Arcangeli gave Feingold detailed information as to the specifications for 9 the programming of the Bionica pump. Dr. Aoki understood that the Australian Bionica pump 10 could be reprogrammed as to both pulse frequency and dosage for his use. (RT Vol. 1 at 140:2– 11 145:25; RT Vol. 10 at 1651:5–1653:4.) 12 38. Around 2001 or 2002, Dr. Aoki learned from Mr. Gilbert himself that he had used 13 $100K of MI’s money to buy Bionica Australia. Mr. Gilbert’s use of MI funds to buy Bionica, 14 concerns about MI’s financial condition especially given Mr. Gilbert’s failure to be forthcoming 15 regarding MI’s financial information, along with Mr. Gilbert’s grant of what Dr. Aoki perceived 16 to be a sweetheart license to his friend, Melanie Kunz, were factors that led Dr. Aoki to request 17 that Mr. Gilbert resign from MI. On October 28, 2002, Mr. Gilbert resigned from MI. (RT Vol 1 18 at 145:22–25; RT Vol. 2 at 198:16–22; 232:3–239:13; 263:11–20; PX 219 (Check for $25,000).) 19 39. On February 23, 2005, CI and Bionica entered into a Development Purchase 20 Agreement, whereby Bionica purchased any rights, title, and interest CI had at that time in and to 21 the AMSys-CI development agreement, purportedly stemming from a default of the development 22 agreement. (PX 66.) Dr. Aoki, however, had never received written notice of a default of the 23 AMSys-CI license, as required under the Modification License (PX 29) nor had he ever received 24 notice that CI intended to issue a license to Bionica. (RT Vol. 2 at 286:7–13.) 25 40. Even if there had been a properly noticed and uncured default resulting in CI 26 acquiring a license to Dr. Aoki’s technology, CI could not have transferred that license to Mr. 27 Gilbert or Bionica without Dr. Aoki’s advance written consent, which consent Dr. Aoki never 28 gave. (PX 24, ¶ 11.1; PX 72 (letter from Aoki to Frank A. Dinucci, President and Executive 1 Director of CI).) 2 41. Moreover, the rights provided under the development agreement in the event of 3 default could not exceed the rights set forth in the underlying AMSys license. The only patent 4 then licensed was the ‘810 patent. (PX 24; PX 29.) 5 42. No Defendant, including Bionica, received legitimate licensing rights via the CI- 6 Bionica license. 7 The Remaining Parties 8 43. Broadly speaking, unless referring to a specific Trina clinic, witnesses referred to 9 “Trina,” “Trina Health,” and “Trina Corporate” interchangeably throughout trial.11 Based on the 10 record as a whole, the Court finds Trina/Trina Health/Trina Corporate was the de facto parent 11 entity of various Trina clinics and was controlled by Mr. Gilbert. As discussed in more detail 12 throughout these Findings of Fact and Conclusions of Law, Trina Health provided licenses and 13 start-up services such as training, materials, and equipment to various clinics nationwide. Those 14 clinics, per their respective license agreements, paid fees to Trina Health. Mr. Gilbert 15 acknowledged the existence of 33 clinics, as discussed below. 16 44. Trina Health of Newport Beach was one of the licensed clinics identified by Mr. 17 Gilbert. Trina Health purchased the clinic from Dr. Rose and Mr. McCarthy. (RT Vol. 11 at 18 1865:6–25.) 19 45. MedEdCo was the medical training and oversight company for Diabetic 20 Innovations. (PX 175.) 21 46. Diabetic Innovations, LLC was an entity formed in Dallas, Texas in 2008 to 22 market Cellular Activation Therapy (“CAT”). (PX 175.) Melanie Kunz and Gregory Gilbert 23 were members of the management team of Diabetic Innovations. (Id.) 24 47. Melanie Kunz was a managing member of MedEdCo. (PX 137.) She was also a 25 nurse practitioner at the Trina Arizona clinic (RT Vol. 7 at 1128:9–14) and through Trina Health 26 taught the treatment process to the Arizona clinic. (RT Vol. 11 at 1971:19–22.) 27

28 11 The Court will refer to this entity as “Trina Health” herein. 1 48. Michael McCarthy, along with Dr. Marc Rose, was among the first to do business 2 as a licensed Trina clinic, under the entity Trina Health of Costa Mesa, which later became Trina 3 Health of Newport Beach. (RT Vol. 10 at 1714:1–1715:10; RT Vol. 11 at 1865:10–15.) 4 49. Marc Rose, M.D., along with Mr. McCarthy, was among the first to do business as 5 a licensed Trina clinic, under the entity Trina Health of Costa Mesa. (RT Vol. 10 at 1714:1– 6 1715:10; RT Vol. 11 at 1865:10–15.) 7 50. Kevin Buckman, M.D. was the medical director of the Trina Sacramento, 8 Roseville, and Hayward clinics at various relevant times. (RT Vol. 6 at 947:24–948:9.) In that 9 position, he oversaw the administration of the APT treatment at those clinics. (RT Vol. 6 at 10 948:10–19; 962:2–9.) 11 51. Timothy Tight was possibly a manager of Trina Health West L.A., but the record 12 is devoid of additional references to this individual. (RT Vol. 9 at 1497:3–7.) 13 52. Faising S. Chui is listed as a manager and organizer of Diabetic Life Pulse of 14 Louisiana, LLC, filed in 2012 with the Louisiana Secretary of State. (PX 162.) Diabetic Life 15 Pulse of Louisiana was a Trina Health licensed clinic operating in Shreveport, Louisiana. (RT 16 Vol. 11 at 1880:16–1881:17.) 17 53. Limi Management is listed as a member and ownership interest of Diabetic Life 18 Pulse of Louisiana, LLC, filed in 2012 with the Louisiana Secretary of State. (PX 162.) 19 54. John Mullen, as CEO and president of Life Pulse Health, LLC, signed a license 20 agreement with Trina Health to open and operate a clinic administering APT. (PX 229.) 21 55. Glenn Wilson, though mentioned as being associated with Mr. Mullen, does not 22 appear in the record or in the exhibits admitted at trial in any meaningful way. 23 56. Richard Girard, though mentioned as being associated with Mr. Mullen, does not 24 appear in the record or in the exhibits admitted at trial in any meaningful way. 25 The RQ Patents and Evidence of Infringement 26 57. The six so-called RQ patents were provisionally filed in 2000 and issued between 27 2003 and 2005. Each patent treats a different complication of diabetes, and the record sometimes 28 refers to them by the condition they aim to treat: (1) heart (‘531 patent); (2) wounds (‘716 patent); 1 (3) kidney (‘342 and ‘527); and (4) eye and nerve (‘736 and ‘191). (See PX 2–7.) 2 58. The patents at issue in this litigation (the “RQ patents”) are: 3 • U.S. Patent No. 6,579, 531 filed June 15, 2001, issued June 17, 2003 (“Method 4 for treating heart disease and cardiovascular disease in diabetic and non- 5 diabetic patients”). 6 • U.S. Patent No. 6,582,716 filed June 15, 2001, issued June 24, 2003 (“Method 7 for treating wounds, promoting healing and avoiding amputations in diabetic 8 and nondiabetic patients”). 9 • U.S. Patent No. 6,613,342 filed June 15, 2001, issued September 2, 2003 10 (“System and method for treating kidney diseases in diabetic and non-diabetic 11 patients”). 12 • U.S. Patent No. 6,613, 736 filed June 15, 2001, issued September 2, 2003 13 (“System and method for treating eye and nerve diseases in diabetic and non- 14 diabetic patients”). 15 • U.S. Patent No. 6,821,527 filed March 19, 2003, issued November 23, 2004 16 (“System for treating kidney disease in diabetic and non-diabetic patients”). 17 • U.S. Patent No. 6,967, 191 filed March 19, 2003, issued November 22, 2005 18 (“System for treating eye and nerve diseases in diabetic and non-diabetic 19 patients”). 20 59. As is relevant to this litigation, Dr. Aoki also owns the original ‘810 patent: U.S. 21 Patent No. 4,826, 810 filed March 19, 1987, issued May 2, 1989 (“System and method for 22 treating animal body tissues to improve the dietary fuel processing capabilities thereof”). 23 60. The RQ patents all follow the same steps with the emphasis on looking at the RQs 24 and trying to increase glucose utilization at the affected or targeted tissue site. (RT Vol. 2 at 25 312:22–24.) 26 61. Those steps are as follows: (1) determine the RQ baseline of the patient; (2) place 27 a needle or catheter into a hand or forearm vein; (3) infuse saline followed by pumps of insulin, 28 using a (Bionica) pump; (4) pulses are administered every 6 minutes, giving 10 pulses in an hour; 1 (5) the amount of insulin per pulse ranges from 10 milliunits to as high as 200 milliunits per 2 kilogram body weight; (6) administer oral glucose, ranging from 40 to 100 grams, determined on 3 an individual basis; (7) after each treatment cycle of ten pulses, the patient is given a rest period 4 (“30 minutes or so”) to allow the high insulin levels to return to/come close to baseline; (8) a 5 typical treatment day consists of three ten-pulse cycles per day; (9) patients get one treatment day 6 per week, but up to three treatment days or more. (RT Vol. 2 at 305:16–312:14.) 7 62. Dr. Aoki testified that these steps are common to all the RQ patents. (RT Vol. 2 at 8 312:15–24.) 9 63. Much of Plaintiffs’ evidence of patent infringement points to two exhibits: the 10 Arizona manual (PX 203) and the 2017 Florida Protocol (PX 228). 11 64. The Arizona manual was used in administering APT in the Arizona clinic. Dr. 12 Elliott testified that the manual was an initial training document and that it provided a “general 13 description” and they “followed the recommendations” with a few adjustments. It sets forth the 14 basic protocol of the treatment. The manual was a collaborative work from other Trina Health 15 clinics and included contributions from the Trina Health of Arizona clinic. (RT Vol. 7 at 16 1136:16–23; 1140:11–18; 1143:7–8; 1154:11–18.) 17 65. Trina Health of Arizona was a licensed Trina Health clinic. (RT Vol. 11 at 18 1863:17–23.) 19 66. Mr. Gilbert also wrote portions of the manual. (RT Vol. 14 at 2376:4–17.) 20 67. The Florida protocol was prepared by Natalie Pereyra, a nurse who worked for the 21 Trina Health of Miami clinic, a clinic licensed by Trina Health. Ms. Pereyra testified that she 22 used a template from the state website and adjusted it with her supervising doctor. (RT Vol. 6 at 23 992:1–14; RT Vol. 11 at 1877:20–1878:5.) 24 68. Nurse Pereyra testified that the actual protocol is much lengthier, but this 25 document contains the “standing orders” between herself and the physician for purposes of 26 administering the treatment, which treatment was called Artificial Pancreas Treatment or 27 Artificial Pancreas System. (RT Vol. 6 at 1000:6–8; 1005:22–25.) 28 69. Additionally, there was a training manual in the very beginning that was left for 1 them during the training. The training manual was brought by administrators from Trina Health 2 of Sacramento to the Miami location to assist in setting up the clinic. (RT Vol. 6 at 1011:6–1012: 3 5.) 4 70. The Court finds Rebecca Shaffer to be a credible witness. Ms. Shaffer was a 5 patient at both the St. Louis (aka Chesterfield), Missouri and Scottsdale, Arizona Trina Health 6 clinics. She was also employed as a sales representative at the Missouri clinic. And she had a 7 background working in the fitness industry, which provides her with some background 8 understanding of the purposes for measuring VCO2 alone versus production of VCO2 as a ratio 9 to consumption of VO2, also known as RQ. (RT Vol. 16 at 2538:19–2539:8; 2541:17–2542:4; 10 2554:17–20; 2602:17–2603:3.) 11 71. It was her understanding that the clinics were using the respiratory quotient 12 (“RQ”) as a way of determining that a patient was responding to the treatment. (RT Vol. 16 at 13 2556:4–25.) Ms. Shaffer testified that given the importance of RQ, the patients at the clinic held 14 a competition amongst themselves to see who could get to the RQ goal of over .90, i.e. to “100 or 15 1.” (RT Vol. 16 at 2609:23–2610:2.) The Court finds this testimony highly credible. 16 72. Ms. Shaffer’s testimony is corroborated by her own patient records which reflect 17 that the Trina Health clinics were in fact using and recording her RQ. (See PX 244A (recording a 18 .70 RQ). The rising RQ values as recorded reflected her body’s response to the treatment. (RT 19 Vol. 16 at 2582:16–23.) 20 73. The license agreements used to set up numerous Trina clinics specifically refer to 21 the patented technology that Defendants claim under the Development Agreement between 22 Bionica and CI. This reference can only reasonably point to the rights to Dr. Aoki’s patented 23 technology. (See PX 94; 95; 98; 99; 104; 105; 108; 109; 229.) 24 74. Cellular Activation Therapy Clinics, LLC (“CATC”) refers to a company set up by 25 Mr. Gilbert and others to license and consult on the opening of clinics. CATC changed its name 26 to Trina Health. (RT Vol. 12 at 2043:7–25.) Despite Mr. Gilbert’s refusal to stipulate that 27 Cellular Activation Therapy (“CAT”) is interchangeable with APT (RT Vol. 2 at 365:20–22), the 28 Court finds CAT was the first name Mr. Gilbert used to identify the treatment later known as 1 APT. (See PX 11.) 2 75. In the CAT presentation, under “Equipment Overview,” it mentions the treatment 3 uses the “Metabolic Measurement (RQ) machine to monitor metabolism.” The presentation then 4 lists the steps of the treatment, which steps not only mirror the general steps of MAT but also 5 explicitly include use of RQ to assess metabolism. There is also a photo of an “RQ Machine” 6 alongside a discussion on measuring metabolism. (PX 11.) 7 76. The April 1, 2015 Trina Health prospectus given to Alabama clinic investors 8 states, “Metabolic Measurement Carts (made by others) are used to determine the metabolic 9 changes (respiratory measurements) of patients under therapy. These Carts are also acquired 10 through Bionica, and are used in the clinic.” (PX 112 at Bates 4615.) 11 77. The 2015 Trina Health article titled, “Introduction to Artificial Pancreas 12 Treatment,” of which Mr. Gilbert wrote “every word” also evidences infringement (as well as 13 misrepresentations). (RT Vol. 12 at 2124:1–2125:3; PX 103.) 14 78. The article states: “Artificial Pancreas Treatment . . . is the only US FDA cleared 15 safe and effective way to stop the progression of diabetes and in most ways reverse the chronic 16 complications of diabetes. . . . The Artificial Pancreas Treatment is the only treatment which 17 addresses this core problem [of improper metabolism], and does so by mimicking the natural way 18 that a pancreas signals a liver to cause proper metabolism.” (PX 103 at Bates 1103.) 19 79. The article also states: “Artificial Pancreas System and Artificial Pancreas 20 Treatment are based on many clinical trials and human treatments, using several names including 21 PIVIT, Metabolic Treatment, CIIIT, etc. They are all part of the evolution of APT.” (PX 103 at 22 Bates 1104.) Yet Mr. Gilbert testified that MAT is also PIVIT. (RT Vol. 15 at 2531:4–5.) 23 80. The article also states that “APT was developed and then tested in a number of 24 university and centers of excellence including Harvard (Joselin) [sic], University of California 25 Davis, University of Arizona, Scripps, Temple University, and the Mayo Clinic, just to name a 26 few . . . .” (PX 103 at Bates P1105.) At least Joslin, UC Davis, and Florida were clinical studies 27 done using Dr. Aoki’s MAT protocol. (RT Vol. 12 at 2048:9–2049:11.) Further, Mr. Gilbert 28 suggests in his testimony he has never done an IRB clinical trial post-Aoki (RT Vol 12 at 2047:2– 1 2048:13) and so the studies referenced above must necessarily refer to MAT. 2 81. The Court finds these statements misleading at best, and suggestive that APT is 3 MAT. At a minimum, these statements are admissions that APT is derived from MAT. The 4 Court finds, however, that any claimed differences between APT and MAT are inconsequential, 5 as discussed below. 6 82. Finally, the article describes the treatment as follows: “Patients treat for 4-5 hours 7 in the clinic once a week for a few weeks, then a[t] most treat once every two to even three 8 weeks. . . . During a treatment day, three infusions are given with the patient sitting in a recliner 9 chair but still able to walk around etc. During the treatments, carbohydrates and intravenous 10 insulin are administered using the Bionica programmed infusion device. The patient stays in the 11 treatment area, and continues to . . . engage in any other passive activity.” (PX 103 at Bates 12 1105.) These treatment steps mirror the MAT protocol suggesting at least three treatment 13 sessions at least once a week with IV insulin infusion using a pump and rest periods where the 14 patient can engage in passive activity. 15 83. More specifically, the Court finds the following evidence demonstrates 16 infringement of each of the claims of the ‘531 patent. 17 18 Claim Evidence of Infringement (1) A method for treating heart disease and • The Arizona manual states treatment 19 cardiovascular disease in diabetic and non- addresses neuropathy, wounds, kidney 20 diabetic patients by improving the dietary disease, retinopathy, and heart disease. fuel capabilities and correct an (PX 203 at Bates 3313–3314.) 21 overutilization of free fatty acids • Nurse Pereyra credibly testified that comprising the steps of: Mr. Gilbert told her the job at the Trina 22 Health licensed Miami clinic would 23 involve administering a treatment for patients who suffered from diabetes 24 complications. (RT Vol. 6 at 1006:2– 10; RT Vol. 11 at 1877:20–25.) 25 • 2015 Trina Prospectus claims APT “is the only clinically proven safe and 26 effective way to treat all of the 27 complications of diabetes.” (PX 112 at Bates 4596; see also PX 11 at Bates 28 1013.) 1 (a) determining a steady baseline • The Arizona manual describes the respiratory quotient of a patient and necessary use of the VacuMed 2 obtaining a subsequent respiratory quotient metabolic measurement cart, which 3 every 30 minutes, the steady baseline measures VCO2 and VO2. The respiratory quotient being two identical manual explains that “this value” 4 consecutive respiratory quotients less than provides information on how well the 0.90 measured five minutes apart, patient is and how he or she is 5 metabolizing fuel sources. (PX 203 at Bates 3384–3385.) 6 • “After a treatment, this value provides 7 information on how well the patient is overcoming metabolic diseases.” (PX 8 203 at Bates 3385.) • Dr. Aoki credibly testified that these 9 two measurements necessarily make up 10 the RQ, that the VacuMed automatically calculates the RER or 11 RQ, and that the RQ is the value that provides information concerning how 12 well a patient is responding, not VCO2 and not VO2 alone. (RT Vol. 2 at 13 299:4 – 305:25; 314:17–24; 317:5– 14 319:24.) • The Arizona manual discusses 15 assessing carbohydrate metabolism before treatment, as well as finding a 16 pre-treatment baseline VO2 and VCO2. (PX 203 at Bates 3386, 3387.) 17 • The manual addresses taking a 18 metabolic measurement, which Dr. Aoki indicated is the RQ, at baseline, 19 one hour, and after all treatments. (PX 203 at Bates 3393; RT Vol. 2 at 332:8– 20 20.) 21 • The Florida Protocol also provides for metabolic measurement at the 22 beginning and end of treatment. (PX 228 at Bates 5771.) 23 • Nurse Pereyra testified that RQ would be given during the metabolic 24 measurement. (RT Vol. 6 at 1005:3– 25 6.) • Per Ms. Shaffer’s testimony, the patient 26 goal was to achieve an RQ of over .90. (RT Vol. 16 at 2609:23–2610:2.) 27 (b) having the patient consume a liquid or • The Arizona manual discusses glucose 28 food containing 60 to 100 grams of load in multiple areas, and specifically 1 glucose, notes the goal of the treatments to maintain blood glucose in a certain 2 range and to ingest glucose during each 3 treatment of 70 to 100 grams. (PX 203 at Bates 3408, 3410.) 4 • The manual also mentions a total of 200 to 300 grams of glucose 5 administered in a treatment session. (PX 203 at Bates 3393.) 6 • Nurse Pereyra additionally testified to 7 the need to keep patient blood glucose levels higher than the norm because the 8 insulin infusions would bring those levels down. (RT Vol. 6 at 1003:15– 9 19.) 10 (c) administering a pulse of insulin through • The Arizona manual mentions insulin an intravenous site at a six minute interval bursts ranging from 10 to 70 mU/kg 11 of time until the subsequent respiratory per burst. (PX 203 at Bates 3397.) quotient shows an improvement over the • The Arizona manual and Florida 12 steady baseline respiratory quotient, the protocol both discuss IV access and use pulse of insulin being 20 to 35 milliunits of of the Bionica pump. (PX 203 at Bates 13 insulin per kilogram of body weight for a 3421, 3396; PX 228 at Bates 5771.) 14 non-diabetic and a Type I diabetic, the • The manual additionally describes APT pulse of insulin being 70 to 200 milliunits as using a “pump that sends pulses of 15 of insulin per kilogram of body weight for insulin intravenously as the patient a Type II diabetic, the improvement over drinks glucose.” (PX 203 at Bates 16 the steady baseline respiratory quotient 3311.) 17 being a respiratory quotient of 0.90 or • The manual provides for 6-minute greater, the subsequent respiratory quotient intervals for pulses. (PX 203 at Bates 18 improvement over the steady baseline 3353, 3398, 3399.) respiratory quotient being a measurement • The Florida protocol outlines pump 19 of increased glucose utilization by a intervals set every 6 minutes for a total diseased myocardium, of 10 per cycle. (PX 228 at Bates 20 5771.) 21 • Nurse Pereyra testified to the same time interval of pulses. (RT Vol. 6 at 22 1003:7–9.) • The Arizona manual acknowledges 23 different ranges of insulin for Type I 24 and Type II, with Type I generally requiring lower doses of insulin and 25 Type II requiring as high as 70mU/kg or above. (PX 203 at Bates 3381.) 26 • The manual acknowledges doses in a range of 10 to 70 mU/kg. (PX 203 at 27 Bates 3397.) 28 • Per Ms. Shaffer’s testimony, the patient 1 goal was to achieve an RQ of over .90. (RT Vol. 16 at 2609:23–2610:2.) 2 (d) allowing the patient to rest one hour, • The Arizona manual references a break 3 and rest period between sessions of 40 to 60 minutes and 15 to 60 minutes. (PX 4 203 at Bates 3313, 3406.) (e) repeating the steps a-d at least three • The Arizona manual provides that a 5 times. typical clinic visit consists of three one- 6 hour sessions with a break between sessions. (PX 203 at Bates 3313.) 7 • The Florida protocol references three cycles per treatment. (PX 228 at Bates 8 5771.) • Nurse Pereyra testified about three- 9 hour sessions. (RT Vol. 6 at 1002:21– 10 24.) (2) The method of claim 1, wherein the • The Arizona manual and Florida 11 intravenous site further comprises a needle protocol both discuss IV access and use or catheter located in the patient’s body, of the Bionica pump. (PX 203 at Bates 12 hand or forearm. 3421, 3396; PX 228 at Bates 5771.) 13 (3) The method of claim 1, wherein the • The Arizona manual and Florida pulse of insulin is administered by an protocol both discuss IV access and use 14 intravenous infusion device. of the Bionica pump. (PX 203 at Bates 3421, 3396; PX 228 at Bates 5771.) 15 (4) The method of claim 1, wherein the • n/a intravenous site is converted to a heparin or 16 a saline lock during step (d). 17 (5) The method of claim 1, wherein said • The Arizona manual indicates steps a–e are repeated at least once a week. treatments are typically once a week, 18 unless and until the time period can be extended. (PX 203 at Bates 3393.) 19 (6) The method of claim 5, wherein said • n/a 20 steps a–e are repeated three or more times a week. 21 22 84. The Court further finds the claims set forth in the ‘716, ‘342, ‘736, ‘527, and ‘191 23 patents are substantially similar if not identical to the claims set forth in the ‘531 patent detailed 24 above. To the extent there are any differences, the ‘531 patent is more limited (such as, for 25 example, by specifying milliunits of insulin administered and/or specifying a wait time of one 26 hour). The evidence cited above therefore supports a finding of infringement of each of the RQ 27 patents. 28 /// 1 Additional Evidence of Infringement 2 85. Mr. Gilbert stated in a July 3, 2013 declaration filed with this Court that he and 3 Bionica have been using Dr. Aoki’s technology with no modifications since at least 2005. (PX 4 93.) Mr. Gilbert testified that the statements made in his declaration are still true and accurate. 5 (RT Vol. 12 at 2116:8–2120:1.) Mr. Gilbert and Bionica apparently relied on the Development 6 Agreement between Bionica and CI in issuing sublicenses to clinics, but as the Court has already 7 found and explained above, Mr. Gilbert and Bionica did not have a valid license to the subject 8 technology. 9 86. Mr. Gilbert additionally testified before this Court that his 2003 declaration in the 10 Nevada action was “all true to this day still.” (RT Vol. 13 at 2154:17.) That declaration 11 explained that the MTC clinics were using Dr. Aoki’s technology. As read into the record, the 12 declaration states: “From and after May 11th, 2003, MTC began and has continued the process of 13 commencing the commercial rollout of the Metabolic Activation Therapy, specifically, with the 14 knowledge and consent of MI, ADRI, [and] Dr. Aoki . . . . The clinics are all using the protocols 15 which were first instituted by Dr. Aoki and have been used at the ADRI for many years. These 16 protocols have been unchanged, and to a greater or lesser extent followed at most other sites. I 17 know of no reason to change these longstanding protocols and, indeed, they are being used by 18 MTC." (RT Vol. 13 at 2153:21–2154:15.) 19 87. Mr. Gilbert’s claim that APT is different from MAT and was his own invention — 20 and specifically to the extent he claims an epiphany in 2002 led to the development of APT and 21 use of APT at MTC clinics (see RT Vol 12 at 2085:15–2087:5) — is therefore contradicted by his 22 own prior sworn declaration and is not credible or believable. 23 Evidence of Use of Slides/Copyright Infringement 24 88. On August 23, 2011, Dr. Aoki obtained copyright registration of his MAT 25 presentation. The copyright is registered with the Copyright Office, number TXu0017772019, 26 and is titled “Metabolic Activation Therapy – History and Current Protocol.” (PX 81 (Copyright 27 Catalog); PX 10A (MAT Presentation Slides).) 28 89. Around 2002, this presentation was given to Mr. Gilbert for the sole purpose of 1 Mr. Gilbert’s education, with instructions not to distribute it. Mr. Gilbert agreed to those 2 conditions. (RT Vol. 12 at 360:2–362:1.) 3 90. Mr. Gilbert acknowledged receiving these slides but disputes the purpose for 4 which he was given them. More specifically, Mr. Gilbert testified that he was given the slides for 5 the purpose of recruiting doctors and patients. He also disputes that the slides were given to him 6 in confidence, with the exception of one particular slide. (RT Vol. 16 at 2646:19–2648:12.) 7 91. The Court finds Dr. Aoki’s testimony more credible. 8 92. The slide deck contains slides of material created by Dr. Aoki from his MAT 9 research, such as photos of patients Dr. Aoki treated and pictorial/graphic representations of the 10 results of his MAT research. (See PX 10A.) Dr. Aoki created some of the materials from his 11 research and others were obtained from other publications and used as part of a presentation. (RT 12 Vol. 2 at 359:16–21). 13 93. Dr. Aoki downloaded PX 11 from diabetes.net, a website under the control of Mr. 14 Gilbert, sometime in 2007 or 2008. Dr. Aoki testified that some of the slides included could only 15 have come from Mr. Gilbert via Dr. Aoki. (RT Vol. 9 at 1454:7–1460:6.) 16 94. PX 11 is a CAT presentation containing a number of reproduced copies of slides 17 from Dr. Aoki’s slide deck. This presentation is evidence that Dr. Gilbert used Dr. Aoki’s slides 18 without his permission prior to Dr. Aoki obtaining a copyright in 2011. 19 95. The vast majority of the evidence showing infringement after 2011 is contained in 20 the 2015 Trina Health Presentation (PX 112) and the Trina Health APT Presentation (PX 12). 21 More specifically, PX 112 and PX 12 contain copies of the slides found in Dr. Aoki’s copyrighted 22 slide deck, PX 10A, at Bates 5840, 5795, 5802, 5804, 5811, 5808, 5821, 5835, 5836, 5837, 5838, 23 5823, 5825, 5827, 5828, 5830, 5831. 24 96. Dr. Aoki downloaded and printed PX 12 from trinahealth.com within the last two 25 years, which website the Court finds to be controlled by Mr. Gilbert for Trina Health. (RT Vol. 9 26 at 1471:12–25.) PX 12 is attributable to Mr. Gilbert and his entities, Trina Health and Bionica. 27 97. Matthew Kalife testified that Mr. Gilbert used the slide deck contained within PX 28 112 to get new investors for Trina Health. (RT Vol. 5 at 783:4–18.) PX 112 is attributable to Mr. 1 Gilbert and his entities. 2 98. Mr. Gilbert also admits that many of the slides used in the Trina Health video clips 3 were slides from Dr. Aoki’s slide deck. (RT Vol. 12 at 2132:9–15.) 4 99. Mr. Gilbert testified that at least one of the slides in question was used to show 5 insulin delivery by the Bionica pump. (RT Vol. 13 at 2367:19–21.) 6 False or Misleading Statements/Misrepresentations 7 100. Defendant Gilbert made numerous false or misleading statements in the course of 8 promoting APT/CAT that either conflate APT and MAT, imply APT is MAT, or indicate MAT 9 never existed (only APT). These statements came from Mr. Gilbert individually and as the 10 president, manager, and/or CEO of both Trina Health and Bionica, in which capacity he signed 11 the Trina clinic license agreements (see, e.g., PX 94, 95). 12 101. Such statements include: using MAT research to support claims about APT (see 13 PX 112); using Dr. Aoki’s MAT slides and attributing them to APT (see PX 11; PX 112); using 14 photos of Dr. Aoki’s MAT patients and indicating they were treated with APT (see PX 11; PX 15 12; PX 112); claiming APT is the only treatment of pulsatile insulin (see PX 11; PX 112); 16 claiming APT has been used for more than 20 years (see PX 126); claiming APT is an FDA- 17 approved treatment when only the Bionica pump is FDA-cleared (not approved) (PX 103 at Bates 18 1103). 19 Evidence of Damages 20 102. Defendants did not produce their financials at any time in course of this litigation. 21 103. Mr. Gilbert confirmed the existence of at least 33 Trina licensed clinics. (RT Vol. 22 11 at 1856:10–1899:1; RT Vol. 14 at 2378:8–9.) 23 104. Mr. Gilbert testified that the number of chairs in these clinics ranged from as few 24 as 2 to as many as 12 to 15. (RT Vol. 13 at 2196:22–25; 2208:21–24.) 25 105. The license agreements reflect these clinics generally paid: (1) a $20K per chair 26 license fee (going as high as $22,500 (see PX 105) and in at least one instance, a $100K per clinic 27 fee, aside from the chair fee (see PX 108)); (2) a one-time $10K training fee; (3) a one-time $500 28 oversight fee; and (4) a royalty fee/cooperation fee ranging from 5% to 13% of gross revenue. 1 (See PX 94; PX 95; PX 98; PX 99; PX 104; PX 105; PX 108 (various Trina Health license 2 agreements).)12 3 106. At trial, Mr. Gilbert did not recall the aggregate amount of chair fees Trina 4 collected for licensing the 33 clinics. He did, however, testify that the aggregate royalties 5 collected — by definition, not including chair fees or other upfront fees — were not more than 6 $5,000 total. (RT Vol. 13 at 2203:1–2204:23.) 7 107. Using an average of 8 chairs per clinic based on Mr. Gilbert’s recollection of the 8 number of chairs in various (but not all) clinics, the Court can reasonably deduce that Mr. Gilbert 9 and his entities collected approximately the following from the Trina license agreements: 10 • 33 clinics x 8 chairs x $20,000 = $5,280,000 11 • 33 clinics x $10K training fee = $330,000 12 • 33 clinics x $500 oversight fee = $16,500 13 ▪ Total: $5,626,500. 14 108. Additionally, the license agreements required licensees to purchase a Bionica 15 pump to administer the patented treatment, defining each clinic to be one pump per chair. Based 16 on an average of 8 chairs per clinic, the Court estimates each clinic purchased on average 8 17 pumps at a unit price of $8,750 (RT Vol. 7 at 1150:12–13; RT Vol. 11 at 1904:12–15; RT Vol. 12 18 at 2026:18–22) to administer the patented treatment, totaling $2,310,000 for 33 clinics. 19 109. Dr. Aoki’s royalty rate as set forth in his 1984 license agreement with AHS was 20 between 1% and 6% (PX 20); in his 1987 license agreement with AMSys was 5% (PX 24); in his 21 2001 license agreement with PAT was 5% (PX 30); and in his 2001 license agreement with MI 22 was 5% (PX 47). 23 110. The license agreements also required the licensees to purchase a Bionica pump to 24 administer the treatment. (See PX 94; PX 95; PX 98; PX 99; PX 104; PX 105; PX 108 (various 25 license agreements).) Mr. Gilbert testified that each pump cost $8,750. (RT Vol. 12 at 2026:18– 26 22.) 27 12 The Court acknowledges that Dr. John Elliott testified to different figures but finds the 28 license agreements to be a more reliable source of these particular data points. 1 II. CONCLUSIONS OF LAW 2 Corporate Defendants with Suspended/Forfeited/Revoked Corporate Status 3 1. An entity with a suspended or forfeited corporate status cannot defend or prosecute 4 civil actions. Accordingly, default judgment is hereby entered against the following Defendants: 5 Bionica Int.’l, LLC; Diabetic Life Pulse of Louisiana, LLC; Diabetic Life Pulse, Inc.; and Life 6 Pulse Health, LLC. 7 Patent Infringement 8 2. Patent infringement is a question of fact. i4i Ltd. v. Microsoft Corp., 598 F.3d 9 831, 849 (Fed. Cir. 2010). The patentee has the burden of proving infringement by a 10 preponderance of the evidence. Duncan Parking Technologies, Inc. v. IPS Group, Inc., 914 F.3d 11 1347, 1360 (Fed. Cir. 2019). 12 3. “[W]hoever without authority makes, uses, offers to sell, or sells any patented 13 invention, within the United States or imports into the United States any patented invention 14 during the term of the patent therefor, infringes the patent.” 35 U.S.C. §271(a). 15 4. As an initial matter, the Court finds no Defendant had legitimate rights to Dr. 16 Aoki’s patented MAT treatment via either the Diabetex or CI line of license agreements. As 17 such, any use of the patents purportedly stemming therefrom constitutes infringement. 18 5. “[S]tatements of fact contained in a brief may be considered admissions of the 19 party in the discretion of the district court. [But] [n]ormally failure to contend that an opposing 20 party's admission barred entry of conflicting evidence is a waiver of the argument that the issue 21 was conclusively settled.” Am. Title Ins. Co. v. Lacelaw Corp., 861 F.2d 224, 227 (9th Cir. 22 1988). 23 6. In the event such admissions cannot be considered conclusive, however, they “still 24 operate as adverse evidentiary admissions properly before the district court in its resolution of the 25 factual issue.” White v. ARCO/Polymers, Inc., 720 F.2d 1391, 1396 (5th Cir. 1983). 26 7. Mr. Gilbert’s statement in his July 3, 2013 declaration that he and Bionica have 27 been using Dr. Aoki’s technology with no modifications since at least 2005 is therefore taken as 28 evidence that APT is not distinct from MAT and, because any rights derived from Diabetex/CI 1 are invalid, such use constitutes literal infringement on the RQ patents. 2 8. Indeed, the development agreements themselves, which reference technology that 3 can only be Dr. Aoki’s MAT treatment, are further evidence of literal infringement. The Court 4 finds this evidence highly persuasive, though not necessarily determinative. 5 9. Aside from an admission of infringement, determining whether a patent has been 6 infringed is generally a two-step analysis. The first step is claim construction. 7 10. Per the parties’ agreement, no separate claim construction hearing took place in 8 this action. The claim terms are given their ordinary meaning as they are understood based on the 9 record before the Court. Indeed, the parties did not and do not dispute the meaning of any terms 10 set forth in the relevant patent claims, and therefore construction is not necessary. 11 11. Plaintiffs have met their burden of establishing patent infringement with respect to 12 Defendants Gilbert, Trina Health, and Bionica. 13 12. “[I]nfringement and validity analyses must be performed on a claim-by-claim 14 basis.” Amazon.com, Inc. v. BarnesandNoble.com, Inc., 239 F.3d 1343, 1351 (Fed. Cir. 2001). 15 “An infringement analysis involves the two-step process of construing the claims and comparing 16 the properly construed claims to the accused product.” Tinnus Enterprises, LLC v. Telebrands 17 Corp., 846 F.3d 1190, 1203 (Fed. Cir. 2017) (internal citation omitted). “To prevail, the plaintiff 18 must establish by a preponderance of the evidence that the accused device infringes one or more 19 claims of the patent either literally or under the doctrine of equivalents.” Bayer AG v. Elan 20 Pharm. Research Corp., 212 F.3d 1241, 1247 (Fed. Cir. 2000). 21 13. “To prove literal infringement, the patentee must show that the accused device 22 contains every limitation in the asserted claims. . . . If even one limitation is missing or not met 23 as claimed, there is no literal infringement.” Mas-Hamilton Group v. LaGard, Inc., 156 F.3d 24 1206, 1211 (Fed.Cir.1998). 25 14. A patent owner “can employ any method of analysis that is probative of the fact of 26 infringement.” Forest Laboratories, Inc. v. Abbott Laboratories, 239 F.3d 1305, 1312 (Fed. Cir. 27 2001). A patent owner may rely on direct or circumstantial evidence in proving infringement. 28 Liquid Dynamics Corp. v. Vaughan Company, Inc., 449 F.3d 1209, 1219 (Fed. Cir. 2006). 1 15. The Court concludes the APT treatment administered at Trina licensed clinics 2 infringed/infringes Dr. Aoki’s MAT treatment as set forth in the RQ patents. Mr. Gilbert, Trina 3 Health, and Bionica are therefore liable for patent infringement. 4 16. More specifically with respect to the ‘531 patent, the Court finds APT infringed on 5 independent Claim 1 and, at a minimum, dependent claims 3 and 5, as based on the evidence set 6 forth in the chart above. 7 17. Because each of the RQ patents protects the identical process as directed to 8 specific complications, the same evidence supports the conclusion that the following patent 9 claims were/are also infringed: 10 • ‘716 patent: independent claim 1 and, at a minimum, dependent claims 3 and 11 5. 12 • ‘342 patent: independent claim 1 and, at a minimum, dependent claims 3, 4, 7, 13 and 8. 14 • ‘736 patent: independent claim 1 and, at a minimum, dependent claims 3, 4, 5, 15 8, and 9. 16 • ‘527 patent: independent claim 1 and, at a minimum, dependent claim 3. 17 • ‘191 patent: independent claim 1 and, at a minimum, dependent claims 3, 4, 18 and 5. 19 18. “Even when an accused product does not meet each and every claim element 20 literally, it may nevertheless be found to infringe the claim if there is ‘equivalence’ between the 21 elements of the accused product or process and the claimed elements of the patented invention.” 22 Intendis GMBH v. Glenmark Pharmaceuticals Inc., USA, 822 F.3d 1355, 1360 (Fed. Cir. 2016) 23 (quoting Warner–Jenkinson Co. v. Hilton Davis Chem. Co., 520 U.S. 17, 21 (1997)). 24 Infringement under the doctrine of equivalents is a question of fact. Id. 25 19. Equivalency should not be considered in a vacuum, and a finding of infringement 26 under the doctrine of equivalents requires a showing that the difference between the claimed 27 invention and the accused product was insubstantial. Graver Tank & Mfg. Co. v. Linde Air Prods. 28 Co., 339 U.S. 605, 608–09 (1950). 1 20. One way of doing so is by showing on an element-by-element basis that the 2 accused product performs substantially the same function in substantially the same way with 3 substantially the same result as each claim limitation of the patented product. Intendis GMBH, 4 822 F.3d at 1360. This is known as the “function-way-result” test. See id. “Each prong of the 5 function-way-result test is a factual determination.” Id. at 1361. 6 21. “An important factor is whether persons reasonably skilled in the art would have 7 known of the interchangeability of an ingredient not contained in the patent with one that was.” 8 Graver Tank & Mfg. Co., 339 U.S. at 609. 9 22. A second way of showing insubstantial difference between the claimed invention 10 and the accused process is the “insubstantial differences” test. UCB, Inc. v. Watson Laboratories 11 Inc., 927 F.3d 1272, 1284 (Fed. Cir. June 24, 2019). “Under the insubstantial differences test, 12 ‘[a]n element in the accused device is equivalent to a claim limitation if the only differences 13 between the two are insubstantial.” Voda v. Cordis Corp., 536 F.3d 1311, 1326 (Fed. Cir. 2008). 14 23. To the extent the evidence indicates APT was different in slight ways from MAT, 15 those differences are insubstantial. As discussed above, the steps of APT mirror those of MAT, 16 indicating overall that APT performs substantially the same function (activation of the liver to 17 improve metabolic processing) using substantially the same way (high pulses of insulin 18 concomitant with a glucose meal) to achieve substantially the same result (improved diabetic 19 complications, i.e. eye, wounds, kidney, heart). 20 24. More specifically, and on a claim-by-claim level, the Court concludes the 21 following. 22 25. To the extent the evidence does not show APT determined a baseline RQ by two 23 identical consecutive RQs measured 5 minutes apart, the Court nevertheless concludes APT 24 infringes this claim under the function-way-result test in that APT identified a pre-treatment 25 baseline RQ, meaning APT performed the same function (obtaining a baseline RQ), in the same 26 way (using an RQ machine or its equivalent), to achieve the same result (a baseline RQ of the 27 patient). 28 26. To the extent the RQ patents claim a subsequent RQ is taken every 30 minutes, 1 this is an insubstantial difference from APT’s claim of measuring the same at one hour and after 2 treatment. 3 27. To the extent the RQ patents claim the patient consumes 60 to 100 grams of 4 glucose, this is an insubstantial difference from APT’s 70 to 100 grams of glucose and APT’s 200 5 to 300 grams of glucose total after 3 sessions because the variation is only slight and the amount 6 consumed necessarily varies between patients, as Dr. Aoki testified. 7 28. Similarly, some of the RQ patents claim that insulin is administered at 20 to 35 8 milliunits per kilogram of body weight and 70 to 200 milliunits per kilogram of body weight. 9 The function, way, and result of APT in administering insulin is the same, regardless of whether 10 APT publications indicate the exact doses. 11 29. The RQ patents’ rest period of one hour is substantially similar to APT’s claimed 12 rest period of 40 to 60 minutes. 13 Indirect Infringement, Inducement 14 30. “Whoever actively induces infringement of a patent shall be liable as an infringer.” 15 35 U.S.C. §271(b). “To prove inducement, the patentee must show direct infringement, and that 16 the alleged infringer ‘knowingly induced infringement and possessed specific intent to encourage 17 another’s infringement.’” i4i Ltd., 598 F.3d at 851. 18 31. Given the decades-long relationship between Mr. Gilbert and Dr. Aoki, and Mr. 19 Gilbert’s involvement with Dr. Aoki’s patent applications, Mr. Gilbert — and therefore the 20 entities he controlled (i.e. Bionica and Trina Health) — knew of Dr. Aoki’s patents, but 21 proceeded to license the technology and open clinics with the specific intent to induce 22 infringement by the downstream licensees. 23 32. As for specific intent, Mr. Gilbert and his entities claimed they were operating 24 under a license where one did not exist. They then shifted to the position that APT is somehow 25 different from MAT, but it is not. Indeed, the license agreements that were entered into 26 specifically reference Dr. Aoki’s patent as the subject technology to be used while failing to 27 disclose Dr. Aoki as the actual owner of these patents. Nor does Mr. Gilbert, have the credentials 28 to invent a wholly new treatment protocol. The only reasonable conclusion when considering all 1 credible evidence above is that Mr. Gilbert’s actions evince a specific intent to encourage others 2 to infringe Dr. Aoki’s patents. 3 Infringement by the Trina Defendants 4 33. What is not clear, however, is whether any Trina Defendant aside from Bionica or 5 Trina Health actually infringed the RQ patents. Indeed, while the record as it pertains to most 6 (but not all) of the Trina Defendants reflects some involvement with Mr. Gilbert, Trina Health, 7 Bionica, and/or one of many Trina clinics, the record is void of any evidence of their direct or 8 indirect infringement. Consequently, the Court finds all Defendants other than Mr. Gilbert, Trina 9 Health, and Bionica not liable for patent infringement. 10 Patent Validity 11 34. “A patent shall be presumed valid. Each claim of a patent (whether in independent 12 or dependent form) shall be presumed valid independently of the validity of other claims; 13 dependent claims shall be presumed valid even though dependent upon an invalid claim. The 14 burden of establishing invalidity of a patent or any claim thereof shall rest on the party asserting 15 it.” 35 U.S.C. § 282. A challenger is required to prove the invalidity of a patent by clear and 16 convincing evidence. i4i Ltd., 589 F.3d at 848. 17 35. At trial and in post-trial filings, Defendants seem to claim Dr. Aoki’s RQ patents 18 are invalid due to anticipation, obviousness, and prior public use (all claims of prior art 19 generally). 20 36. “To show that a patent claim is invalid as anticipated, the accused infringer must 21 show by clear and convincing evidence that a single prior art reference discloses each and every 22 element of a claimed invention.” Silicon Graphics, Inc. v. ATI Technologies, 607 F.3d 784, 796 23 (Fed. Cir. 2010). A prior art reference does not invalidate a patent if it merely “suggests” the 24 claimed subject matter. AstraZeneca LP v. Apotex, Inc., 633 F.3d 1042, 1055 (Fed. Cir. 2010). 25 To prove anticipation, the alleged infringer must show that “one skilled in the art would 26 reasonably understand or infer from a [prior art reference] that every claim element is disclosed in 27 that reference.” Id. (internal citation omitted). 28 37. Defendants have not provided clear and convincing evidence of invalidity by prior 1 art and have therefore failed to meet their burden. 2 38. The assertion that the RQ patents were anticipated by prior art embodied in the 3 ‘810 patent (or elsewhere) has no support in evidence, nor have Defendants attempted to 4 demonstrate that each claim was disclosed in the ‘810 patent. 5 39. “A patent for a claimed invention may not be obtained . . . if the differences 6 between the claimed invention and the prior art are such that the claimed invention as a whole 7 would have been obvious before the effective filing date of the claimed invention to a person 8 having ordinary skill in the art to which the claimed invention pertains.” 35 U.S.C. §103. 9 Obviousness is a question of law based on underlying facts including: (1) the scope and content 10 of the prior art; (2) the differences between the prior art and the claimed invention; (3) the level of 11 ordinary skill in the field of the invention; and (4) any relevant objective considerations of 12 nonobviousness. Graham v. John Deere Co. of Kan. City, 383 U.S. 1, 17–18 (1966); see also 13 Mobilemedia Ideas LLC v. Apple Inc., 780 F.3d 1159, 1167 (Fed. Cir. 2015). 14 40. A person of ordinary skill in the art is a hypothetical person who is presumed to 15 have known the relevant prior art at the time of the invention. Factors that may be considered in 16 determining the level of ordinary skill in the art may include: (1) “type of problems encountered 17 in the art;” (2) “prior art solutions to those problems;” (3) “rapidity with which innovations are 18 made;” (4) “sophistication of the technology;” and (5) “educational level of active workers in the 19 field." In re GPAC Inc., 57 F.3d 1573, 1579 (Fed. Cir. 1995). 20 41. “One of the ways in which a patent's subject matter can be proved obvious is by 21 noting that there existed at the time of invention a known problem for which there was an obvious 22 solution encompassed by the patent's claims.” KSR International Co. v. Teleflex, 550 U.S. 398, 23 420–21 (2001). A court should not use the benefit of hindsight in assessing obviousness. Id. at 24 421. 25 42. Obviousness is assessed on a claim-by-claim basis. Aventis Pharma Deutchsland 26 GmbH v. Lupin Ltd., 499 F.3d 1293, 1303 (Fed. Cir. 2007). 27 43. Defendants have not provided clear and convincing evidence of obviousness and 28 have therefore failed to meet their burden. To the contrary, the record supports a finding that the 1 technology patented by the RQ patents was anything but obvious to a person of ordinary skill in 2 the art at the time Dr. Aoki was developing his methodology and protocol. 3 44. A person is not entitled to a patent if “the claimed invention was patented, 4 described in a printed publication, or in public use, on sale, or otherwise available to the public 5 before the effective filing date of the claimed invention.” 35 U.S.C. §102(a)(1). Under § 102(b) 6 the invention may be sold up to one year before the filing of the patent application. If on sale 7 “more than one year before the filing of an application for a patent on the governing claims, any 8 issued patent is invalid . . . .” Medicines Company v. Hospira, Inc., 827 F.3d 1363, 1365 (Fed. 9 Cir. 2016). 10 45. For determining whether the public use or on-sale bar applies, the Supreme Court 11 had adopted a two-prong test. Pfaff v. Wells Electronics, Inc., 525 U.S. 55, 67 (1998). First, the 12 claimed invention must be the subject of a commercial offer for sale and, second, the claimed 13 invention was ready for patenting. Id. 14 46. “[E]xperimental use negates invalidity under the public use bar.” Barry v. 15 Medtronic, Inc., 914 F.3d 1310, 1321 (Fed. Cir. 2019); see also id., at 1337 (dissenting opinion 16 noting that “Even if a patent challenger makes out a prima facie case of the on-sale bar, a patentee 17 may negate the bar's application with evidence that the sale was primarily for experimental 18 purposes.”). 19 47. A use may be experimental only if its purpose is: “(1) [to] test claimed features of 20 the invention or (2) to determine whether an invention will work for its intended purpose — itself 21 a requirement of patentability. . . . Indeed, the experimental use negation of the § 102(b) bar only 22 exists to allow an inventor to perfect his discovery through testing without losing his right to 23 obtain a patent for his invention.” Clock Spring, L.P. v. Wrapmaster, Inc., 560 F.3d 1317, 1327 24 (Fed. Cir. 2009). 25 48. “A use or sale is experimental for purposes of [§] 102(b) if it represents a bona 26 fide effort to perfect the invention or to ascertain whether it will answer its intended purpose.… 27 If any commercial exploitation does occur, it must be merely incidental to the primary purpose of 28 the experimentation to perfect the invention.” LaBounty Mfg. v. United States Int’l Trade 1 Comm’n, 958 F.2d 1066, 1071 (Fed. Cir. 1992) (citation omitted). 2 49. Courts have considered a number of factors in determining whether a claimed 3 invention was the subject of a commercial offer for sale primarily for purposes of 4 experimentation. These factors include: (1) the necessity for public testing; (2) the amount of 5 control over the experiment retained by the inventor; (3) the nature of the invention; (4) the length 6 of the test period; (5) whether payment was made; (6) whether there was a secrecy obligation; (7) 7 whether records of the experiment were kept; (8) who conducted the experiment; (9) the degree of 8 commercial exploitation during testing; (10) whether the invention reasonably requires evaluation 9 under actual conditions of use; (11) whether testing was systematically performed; (12) whether 10 the inventor continually monitored the invention during testing; and (13) the nature of contacts 11 made with potential customers. Allen Eng’g Corp. v. Bartell Indus., Inc., 299 F.3d 1336, 1353 12 (Fed. Cir. 2002). 13 50. “Whether the on-sale bar applies is a question of law based on underlying factual 14 findings.” Medicines Company v. Hospira, Inc., 827 F.3d 1363, 1365 (Fed. Cir. 2016). 15 51. Defendants have not provided clear and convincing evidence of prior public 16 use/applicability of the on-sale bar and have therefore failed to meet their burden. 17 52. To the contrary, all use of MAT before 1999 was experimental and any payment 18 derived therefrom was “incidental to the primary purpose of the experimentation to perfect the 19 invention.” LaBounty Mfg., 958 F.2d at 1071. 20 53. On balance, the thirteen factors enumerated above indicate Dr. Aoki’s treatment of 21 patients for diabetic complications before 1999 was experimental. As discussed above, Dr. Aoki 22 testified that as of the 1990s, he was indeed using the RQ, but on an experimental basis. He had 23 not yet reduced it to an actual treatment methodology as his focus was on improving glucose 24 control. He had not settled on the final adjustments for how often he was going to measure RQ 25 and how to address the treatment if he was looking for other physiological results outside of 26 glucose control. In the late 1990s Dr. Aoki noticed that despite glucose control getting worse, 27 some of the complications he was studying were stable. Dr. Aoki testified that specifically after 28 1999, he decided to do a baseline RQ followed by an RQ after one, two and three hours. He also 1 increased the amount of pulsed insulin and frequency of treatment days and began looking to see 2 if the complications were responding to these changes, which they did. Prior to 1999, Dr. Aoki’s 3 focus was still on improving glucose control and any use of RQ up to that point was 4 experimental. Dr. Aoki retained control over the testing and, given the nature of both the industry 5 and the invention, it is logical that extensive testing was prudent. 6 54. None of the exhibits relied upon by Defendants negate Dr. Aoki’s testimony that 7 prior to1999, he was performing his treatment using RQ to treat diabetic complications on an 8 experimental basis and had not yet reduced to practice the steps for the complications that were 9 ultimately patented. Dr. Aoki was treating patients and focusing on blood glucose control prior to 10 1999. He wasn’t charging for treatment of complications. 11 Copyright Infringement 12 55. The Copyright Act grants the copyright owner the exclusive right to reproduce a 13 copyrighted work, to distribute copies of the work, and to authorize reproduction or distribution. 14 See 17 U.S.C. §106(1), (3). To prevail on a claim of copyright infringement, a plaintiff must 15 prove: (1) ownership of a valid copyright and (2) that the defendant violated at least one exclusive 16 right granted to plaintiff under 17 U.S.C. §106. A & M Records, Inc. v. Napster, Inc., 239 F.3d 17 1004, 1013 (9th Cir. 2001). 18 56. Defendants argue many — but not all — of Dr. Aoki’s slides present factual data 19 that is not properly copyrightable. They also assert any use falls within the fair use doctrine. 20 57. “Unlike a patent, a copyright gives no exclusive right to the art disclosed; 21 protection is given only to the expression of the idea — not the idea itself." Mazer v. Stein, 347 22 U.S. 201, 217 (1954). 23 58. “[T]he fair use of a copyrighted work, including such use by reproduction in 24 copies . . . or by any other means specified by that section, for purposes such as criticism, 25 comment, news reporting, teaching (including multiple copies for classroom use), scholarship, or 26 research, is not an infringement of copyright.” 17 U.S.C. § 107. 27 59. In determining whether the use made of a work in any particular case is a fair use, 28 the factors to be considered shall include: (1) the purpose and character of the use, including 1 whether such use is of a commercial nature or is for nonprofit educational purposes; (2) the nature 2 of the copyrighted work; (3) the amount and substantiality of the portion used in relation to the 3 copyrighted work as a whole; and (4) the effect of the use upon the potential market for or value 4 of the copyrighted work. 17 U.S.C. § 107. The court is to consider and weigh the factors 5 together, not in isolation, and in light of the purpose of copyright to promote science and the arts. 6 Campbell v. Acuff-Rose Music, Inc., 510 U.S. 569, 578 (1994). 7 60. The proponent of fair use has the burden of demonstrating fair use. Campbell v. 8 Acuff-Rose Music, Inc., 510 U.S. 569, 590 (1994). 9 61. Defendants concede that, at a minimum, the slides containing photographs of Dr. 10 Aoki’s patients are copyrightable. Additionally, the Court finds Dr. Aoki’s body of work as a 11 whole is an expression of his ideas and innovation, he was not simply reproducing facts. 12 62. The record establishes that the use of the slides in various contexts, as set forth in 13 the findings of fact, was not fair use. Indeed, in light of the Court’s finding of patent 14 infringement it is clear Mr. Gilbert’s use of the slides was not “transformative.” Rather, while he 15 may have added to certain images, the images are nonetheless simply copied and used as if the 16 findings were the result of APT. The slides themselves represent and reflect Dr. Aoki’s life’s 17 work, including the results of studies surrounding his MAT treatment. Mr. Gilbert used those 18 images for the commercial purpose of soliciting and informing potential investors about Trina, 19 Bionica, and APT. Defendants put forth no evidence concerning the effect of their use on the 20 market for or value of the copyrighted work but based on the evidence the Court concludes that, 21 at best, Mr. Gilbert’s use caused confusion in the market by representing the slides were the 22 product of APT and not MAT. 23 63. Plaintiffs have sufficiently met their burden of proving Dr. Aoki’s ownership of a 24 valid copyright in the MAT slide deck (PX 10A) and have further proved Defendants Gilbert, 25 Bionica, and Trina Health have reproduced the copyrighted work in violation of 17 U.S.C. § 26 106(1). Defendants have failed to meet their burden of establishing any use was a fair use and 27 therefore Mr. Gilbert, Bionica, and Trina Health are liable for copyright infringement. 28 64. The record is devoid of evidence of copyright infringement on the part of the other 1 Trina Defendants. 2 False and Misleading Advertising and Unfair Competition: Lanham Act 3 65. The following five elements make up a false advertising claim under § 43(a) of the 4 Lanham Act, 15 U.S.C. §1115(a): (1) a false statement of fact by the defendant in a commercial 5 advertisement about its own or another’s product; (2) the statement actually deceived or has the 6 tendency to deceive a substantial segment of its audience; (3) the deception is material, in that it 7 is likely to influence the purchasing decision; (4) the defendant caused its false statement to enter 8 interstate commerce; and (5) the plaintiff has been or is likely to be injured as a result of the false 9 statement, either by direct diversion of sales from itself to defendant or by a lessening of the 10 goodwill associated with its products. Skydive Ariz., Inc. v. Quattrocchi, 673 F.3d 1105, 1110 11 (9th Cir. 2012). 12 66. To constitute a statement made in a commercial advertisement, the statement must 13 be: (1) commercial speech; (2) by the defendant who is in commercial competition with the 14 plaintiff; (3) for the purpose of influencing consumers to buy defendant’s goods or services; and 15 (4) must be disseminated sufficiently to the relevant purchasing public to constitute “advertising” 16 or “promotion” within that industry. The representations need not be made in a “classic 17 advertising campaign,” but may consist instead of more informal types of “promotion.” Newcal 18 Indus., Inc. v. Ikon Office Solution, 513 F.3d 1038, 1054 (9th Cir. 2008). 19 67. The Act distinguishes between advertisements that are literally false and those that 20 are literally true, but misleading. When the advertising is literally false, a court may grant relief 21 without reference to the advertisements’ impact on the buying public. In re Century 21 RE/MAX 22 Advert. Claims Litig., 882 F. Supp. 915, 922 (C.D. Cal. 1994). 23 68. Where a statement is not literally false, but is only misleading in context, proof 24 that the advertising actually conveyed the implied message and thereby deceived a significant 25 portion of the consuming public is required. William H. Morris Co. v. Group W, Inc., 66 F.3d 26 255, 258 (9th Cir. 1995). The only exception to this proof requirement arises when the plaintiff 27 intentionally deceives consumers. Harper House, Inc. v. Thomas Nelson, Inc., 889 F.2d 197, 209 28 (9th Cir. 1989). 1 69. Mr. Gilbert, individually and in his capacity as president, manager, and/or CEO of 2 Bionica, and/or Trina Health made statements about APT that are both literally false and/or 3 misleading in various APT promotional materials. Where those statements were literally false — 4 as in, most obviously, claiming APT was FDA-cleared, claiming certain patient outcomes were 5 the result of APT when they depicted MAT results, and claiming APT was the only treatment of 6 its kind — the Court need not consider the impact of those statements on the public. See In re 7 Century 21 RE/MAX Advert. Claims Litig., 882 F. Supp. at 922. 8 70. To the extent certain statements by Defendants were not literally false but were 9 misleading — as in, for example, construing the claim that APT was the only treatment to mean 10 that APT was being administered under a purported license agreement to the MAT technology, 11 and APT and MAT are therefore the same (and only) treatment — the Court finds such 12 statements to be intentionally deceptive and therefore within the exception set forth in Harper 13 House, 889 F.2d at 209. 14 71. The record supports a finding that Mr. Gilbert made the above statements 15 individually and on behalf of Bionica and Trina Health knowing they were false and with the 16 intent to deceive prospective patients and investors. That deception was material in that FDA 17 clearance, patient outcomes, and exclusivity, for example, are likely to influence both investors’ 18 and patients’ decisions. 19 72. The false or misleading statements have or are likely to injure Dr. Aoki and ADRI 20 by lessening their goodwill and any goodwill associated with MAT. Indeed, Mr. Gilbert and 21 Trina have infringed on Dr. Aoki’s patents and used that technology to set up their own clinics, 22 intentionally muddying the waters concerning who is the inventor and rightful owner of the 23 patented technology. Mr. Gilbert’s scheme to open Trina clinics and mislead patients and 24 investors into believing either (1) that APT is the only FDA cleared treatment which has itself 25 undergone decades of studies, and/or (2) that APT and MAT are the same, certainly has the effect 26 of tarnishing Dr. Aoki’s reputation concerning his research and protocol. 27 73. There is no evidence in the record indicating any other Trina Defendant made any 28 false or misleading statement. 1 74. To the extent such false advertising constitutes unfair competition under the 2 Lanham Act, the same findings of fact apply to the latter, and Mr. Gilbert and Trina are liable for 3 the same. 4 FAL and UCL: Cal. Bus. & Prof. Code §§ 17500 and 17200 5 75. California's False Advertising Law (“FAL”) prohibits the dissemination of false or 6 misleading statements in connection with advertising. Cal. Bus. & Prof. §17500. “Section 17500 7 has been broadly construed to proscribe ‘not only advertising which is false, but also advertising 8 which[,] although true, is either actually misleading or which has a capacity, likelihood or 9 tendency to deceive or confuse the public.’” Colgan v. Leatherman Tool Group, Inc., 135 10 Cal.App.4th 663, 679 (2006) (citation omitted). 11 76. “Actual reliance, or causation, is inferred from the misrepresentation of a material 12 fact.” Chapman v. Skype, Inc., 220 Cal.App.4th 217, 229 (2013) (citing In re Tobacco II Cases, 13 46 Cal.4th 298, 327 (2009). 14 77. “A misrepresentation is judged to be ‘material’ if a reasonable man would attach 15 importance to its existence or nonexistence in determining his choice of action in the transaction 16 in question . . . .” Kwikset Corp. v. Superior Court, 51 Cal.4th 310, 332-333 (2011) (internal 17 citations omitted). 18 78. Cal. Bus. & Prof. Code § 17200 defines “unfair competition” to include “any 19 unlawful, unfair or fraudulent business act or practice” and “unfair, deceptive, untrue or 20 misleading advertising” as well as any act that violates California’s FAL. A violation of the FAL 21 therefore also constitutes a violation of the UCL. Kasky v. Nike, Inc., 27 Cal.4th 939, 950 (2002). 22 79. Additionally, the UCL covers the following theories of liability: (1) unlawful 23 business acts or practices; (2) unfair business acts or practices; (3) fraudulent business acts or 24 practices; and (4) unfair, deceptive, untrue or misleading advertising. Cel-Tech Communications, 25 Inc. v. Los Angeles Cellular Telephone Co., 20 Cal.4th 163, 180 (1999). 26 80. To prevail on a claim under the FAL and UCL, a plaintiff must “(1) establish a 27 loss or deprivation of money or property sufficient to qualify as injury in fact, i.e., economic 28 injury, and (2) show that the economic injury was the result of, i.e., caused by, the unfair business 1 practice or false advertising that is the gravamen of the claim.” Kwikset Corp., 51 Cal.4th at 322. 2 This is a narrower standing requirement than Article III’s actual injury requirement. Id. 3 81. “There are innumerable ways a plaintiff may demonstrate economic injury, 4 including the following: [a] plaintiff may (1) surrender in a transaction more, or acquire in a 5 transaction less, than he or she otherwise would have; (2) have a present or future property 6 interest diminished; (3) be deprived of money or property to which he or she has a cognizable 7 claim; or (4) be required to enter into a transaction, costing money or property, that would 8 otherwise have been unnecessary. Courts have also found lost sales, revenue, market share, and 9 asset value sufficient to allege an economic injury.” Obesity Research Institute, LLC v. Fiber 10 Research Int’l, LLC, 165 F. Supp. 3d 937, 947–48 (S.D. Cal. 2016). 11 82. Plaintiffs have not met their burden of establishing an economic injury caused by 12 Defendants’ false advertising. While Plaintiffs may otherwise be entitled to the profits certain 13 Defendants unlawfully garnered, Plaintiffs have proffered no evidence that they lost profits, were 14 unable to open clinics, or otherwise lost money or property as a result of the deceptive statements 15 discussed above, as required under the UCL and FAL. Although goodwill is a protected property 16 interest and harm to goodwill is a cognizable injury, see Soranno's Gasco, Inc. v. Morgan, 874 17 F.2d 1310, 1316 (9th Cir.1989), Plaintiffs presented no evidence of the value of their goodwill or 18 an economic harm stemming from the loss of goodwill. 19 83. To the extent Plaintiffs’ UCL claim is premised not on false advertising but on the 20 underlying patent and/or copyright infringement, such claim is preempted by federal law. 21 Deckers Outdoor Corp. v. Fortune Dynamic, Inc., No. CV 15-769 PSG (SSX), 2015 WL 22 12731929, at *7–8 (C.D. Cal. May 8, 2015) (“[T]he alleged unfair conduct is simply Defendants' 23 [actions] that infringe on Plaintiff's patent. This theory of wrongful conduct is not ‘qualitatively 24 different’ than a claim for patent infringement based on that conduct; therefore, the unfair 25 competition claims premised on this theory are preempted by the Patent Act.”) 26 84. As a result, the Court finds Plaintiffs have not sufficiently proven their claims 27 arising under the UCL or FAL as asserted against any Defendant. 28 /// 1 Breach of Fiduciary Duty and Confidentiality as to Mr. Gilbert 2 85. The elements of a claim for breach of fiduciary duty are the existence of a 3 fiduciary relationship, breach of fiduciary duty, and damages. Oasis West Realty, LLC v. 4 Goldman, 51 Cal.4th 811, 820 (2011). Among those fiduciary obligations are the duties of 5 loyalty and confidentiality, which continue in force even after the representation ends. Id. 6 86. “[A]n attorney is forbidden to do either of two things after severing [the] 7 relationship with a former client. [The attorney] may not do anything which will injuriously 8 affect [the] former client in any matter in which [the attorney] formerly represented [the client] 9 nor may [the attorney] at any time use against [the] former client knowledge or information 10 acquired by virtue of the previous relationship.” Id. at 821 (citations omitted). 11 87. A confidential relationship exists between two persons “when one has gained the 12 confidence of the other and purports to act or advise with the other’s interest in mind” and “may 13 exist although there is no fiduciary relation” and “is particularly likely to exist where there is a 14 family relationship or one of friendship . . . .” Davies v. Krasna, 14 Cal.3d 502, 510 (1975). A 15 “confidential relationship exists when trust and confidence are reposed by one person in the 16 integrity and fidelity of another.” Estate of Sanders, 40 Cal.3d 607 (1985) (citations omitted). It 17 is not necessary that “there be an extended period of business or accommodation transactions or 18 dealings between persons in order for a confidential relationship to be established between them.” 19 Id. (citations omitted); see also Richelle L. v. Roman Catholic Archbishop, 106 Cal.App.4th 257, 20 271 (2003) (citations omitted) (“Technically, a fiduciary relationship is a recognized legal 21 relationship such as . . . attorney and client, whereas a confidential relationship may be founded 22 on a moral, social, domestic, or merely personal relationship as well as on a legal relationship.”) 23 88. The Court finds Mr. Gilbert breached his fiduciary duty and duty of confidentiality 24 to Dr. Aoki and ADRI. 25 89. The record establishes the following: Mr. Gilbert was the attorney for ADRI and 26 Dr. Aoki personally for many years. In that capacity, he worked closely with Dr. Aoki and 27 ADRI, and obtained confidential information regarding Dr. Aoki’s technology (which would 28 ultimately be embodied in the RQ patents). Mr. Gilbert advised on the formation of a number of 1 business entities to commercialize Dr. Aoki’s technology and drafted and reviewed documents in 2 connection with that enterprise, spanning multiple business entities. Mr. Gilbert obtained a copy 3 of Dr. Aoki’s MAT slides with instructions not to disseminate. Put most succinctly, the 4 relationship between Dr. Aoki and Mr. Gilbert deteriorated beginning in or around 2002. 5 Thereafter, Mr. Gilbert began opening clinics using Dr. Aoki’s technology. He used Dr. Aoki’s 6 slides to promote his enterprise, both before and after they were copyrighted. Mr. Gilbert claimed 7 and still claims he was operating under a license agreement from CI that he concealed from Dr. 8 Aoki and which the Court ultimately finds invalid. Mr. Gilbert also claimed he obtained license 9 rights via the Diabetex settlement, which the Court also finds invalid. Mr. Gilbert also claims to 10 be operating under a new technology that he himself invented. The Court finds this to be 11 disingenuous as well. 12 90. These facts support the conclusion that Mr. Gilbert used information and 13 knowledge gained from his decades-long relationship with ADRI and Aoki to his former clients’ 14 detriment, even beyond the scope of Plaintiffs’ federal law claims. This amounts to a breach of 15 both fiduciary duty and confidentiality. 16 III. REMEDIES 17 Patent Infringement Remedies 18 1. Upon a finding of patent infringement, “the court shall award the claimant 19 damages adequate to compensate for the infringement, but in no event less than a reasonable 20 royalty for the use made of the invention by the infringer, together with interest and costs as fixed 21 by the court.” 35 U.S.C. §284. 22 2. The patentee has the burden of proving damages and must do so by a 23 preponderance of the evidence. Lucent Techs., Inc. v. Gateway, Inc., 580 F.3d 1301, 1324 (Fed. 24 Cir. 2009). “Two alternative categories of infringement compensation are the patentee's lost 25 profits and the reasonable royalty he would have received through arms-length bargaining.” Id. 26 3. It does not appear Plaintiffs seek lost profits, nor is there evidence in the record to 27 establish such a figure. 28 4. “A reasonable royalty may be based upon an established royalty, if there is one, or 1 if not, upon the supposed result of hypothetical negotiations between the plaintiff and defendant. 2 The hypothetical negotiation requires the court to envision the terms of a licensing agreement 3 reached as the result of a supposed meeting between the patentee and the infringer at the time 4 infringement began.” Minks v. Polaris Industries, Inc., 546 F.3d 1364, 1372 (Fed. Cir. 2008). 5 5. This approach typically includes consideration of the “Georgia-Pacific factors,” a 6 set of factors set forth in Georgia-Pacific Corp. v. U.S. Plywood Corp., 318 F. Supp. 116, 1120 7 (S.D.N.Y. 1970). See, e.g., Lucent Technologies v. Gateway, 580 F.3d 1301, 1324 (Fed. Cir. 8 2009). 9 6. Georgia-Pacific outlines fifteen factors that may be considered. As is relevant 10 here, two of those factors are: (1) the royalties received by the patentee for the licensing of the 11 patent in suit, proving or tending to prove an established royalty; and (2) the rates paid by the 12 licensee for the use of other patents comparable to the patent in suit. Georgia-Pacific Corp., 318 13 F. Supp. at 1120. 14 7. Damages awarded for patent infringement “must reflect the value attributable to 15 the infringing features of the product, and no more.” Ericsson, Inc. v. D-Link Sys., Inc., 773 F.3d 16 1201, 1226 (Fed. Cir. 2014). 17 8. Apportioning patent infringement damages ensures that patentees are compensated 18 only for the value of what they invented. Uniloc USA, Inc. v. Microsoft Corp., 632 F.3d 1292, 19 1318 (Fed. Cir. 2011) (The patentee “must in every case give evidence tending to separate or 20 apportion the defendant’s profits and the patentee’s damages between the patented feature and the 21 unpatented features, and such evidence must be reliable and tangible, and not conjectural or 22 speculative . . . .”). 23 9. “The entire market value rule allows a patentee to assess damages based on the 24 entire market value of the accused product only where the patented feature creates the ‘basis for 25 customer demand’ or ‘substantially create[s] the value of the component parts.’” Id. (citing 26 Lucent Techs., 580 F.3d at 1336.) 27 10. As a preliminary matter, the Court notes the record as a whole is painfully lacking 28 in terms of concrete evidence of damages. The parties’ respective proposed findings of fact and 1 conclusions of law contribute little to the discussion of remedies in general. Despite a finding of 2 liability, the Court can only award damages that are sufficiently established by Plaintiffs. The 3 Court is acutely aware, however, that this void is caused largely by Defendants’ refusal to 4 produce financial records, even after a protective order was in place and even after the magistrate 5 judge issued sanctions in connection with a failure to produce discovery. 6 11. Here, the evidence in the record includes two kinds of license agreements that are 7 potentially relevant to determining a reasonable royalty. 8 12. First, Dr. Aoki licensed the subject technology first to PAT (PX 39) and then to 9 MI (PX 47) in 2001. Those licenses were intended to commercialize Dr. Aoki’s treatment, and 10 specifically cover what at that time were identified as patent applications for the RQ patents. The 11 royalty rate set forth in those agreements is a running royalty of 5% of all commercial sales. 12 13. Second, Trina Health (via Mr. Gilbert and Bionica) purported to license the same 13 subject technology to various clinic entities from at least 2013 to 2016 (PX 94, 95, 98, 99, 104, 14 105, 108). Based on the seven examples before the Court, those license agreements provide for 15 the payment of chair fees, oversight fees, and training fees, in addition to a running royalty of 5% 16 to 13% of gross revenue. There were 33 clinics in all. 17 14. In attempting to fashion a reasonable royalty, the Court essentially attempts to 18 construe what a license between Plaintiffs and Defendants Gilbert, Trina Health, and Bionica for 19 the subject technology would have looked like. While Plaintiffs urge the Court to find 20 Defendants’ various clinic licenses are the best evidence of a reasonable royalty, including the 21 start up fees for the right to practice the claimed invention, the Court finds these license 22 agreements are not sufficiently comparable to the hypothetical license between Plaintiffs and 23 Defendants. To the contrary, and even though those licenses purported to license the same 24 technology, those license agreements were actually sub-licenses, entered as a means of starting 25 treatment clinics. Had Plaintiffs and Defendants entered into a valid agreement whereby 26 Plaintiffs licensed the subject technology to Defendants, it is more likely such a license would 27 provide Defendants the right to sub-license the technology and open clinics (as they did without 28 such rights), and would provide a more standard royalty to Plaintiffs. Indeed, Dr. Aoki’s license 1 to MI was for the purpose of MI then contracting with ADTC to open clinics. The Court can 2 conceive of a similar arrangement between Plaintiffs and Defendants here for the ultimate 3 purpose of starting Trina clinics.13 4 15. The best evidence of a reasonably royalty is therefore the established royalty set 5 forth in Dr. Aoki’s licenses to PAT and MI, both of which provide commercialization rights to 6 the licensee in exchange for a royalty of 5% of all Commercial Sales [as defined] based on the 7 Net Selling Price or Net Revenues [as defined]. (See PX 39, PX 47.) 8 16. Determining a base for that royalty rate is a difficult task due to the lack of 9 evidence of financials in this matter. The Plaintiffs have sufficiently proven, however, that 10 Defendants collected $7,936,500 in chair fees, training fees, oversight fees, and pump sales across 11 the 33 clinics. Mr. Gilbert also testified that the aggregate royalties collected from all clinics — 12 by definition, not including chair fees or other upfront fees — were not more than $5,000 total. 13 The Court finds the entirety of this sum was garnered as a result of the infringement under the 14 entire market rule because the RQ patents substantially create the value of the license agreements. 15 17. As Defendants proffered no evidence in the way of costs to offset those figures, 16 the Court concludes a total of $7,941,500 is an appropriate base. Using the reasonable royalty of 17 5%, Plaintiffs are entitled to damages totaling $397,075 for Defendants’ infringement of the 18 patents at issue. 19 18. The Court may increase damages up to three times the amount found. 35 U.S.C. § 20 284. 21 19. Such an enhancement is “designed as a ‘punitive’ or ‘vindictive’ sanction for 22 egregious infringement behavior. The sort of conduct warranting enhanced damages has been 23 variously described in our cases as willful, wanton, malicious, bad-faith, deliberate, consciously 24 wrongful, flagrant . . . .” Halo Elecs., Inc. v. Pulse Elecs., Inc., 136 S. Ct. 1923, 1932 (2016). 25 20. The Court finds the record supports an enhancement of three times the amount 26 13 Given the bad blood between the parties, the Court is aware such an agreement would not 27 have actually taken place at the time of the infringement. But that is not relevant to the hypothetical negotiations discussed herein, which presume the parties would enter into an arm’s 28 length transaction. 1 found. Mr. Gilbert used his position as a fiduciary to garner access to and understanding of Dr. 2 Aoki’s technology which ultimately allowed him to infringe the patents, demonstrating bad-faith. 3 Moreover, his conduct in first claiming a purported license right to the technology, withholding 4 the existence of the CI-Bionica license, opening clinics using the patented technology, and 5 claiming the treatment effects of MAT to be those of APT demonstrate willful and consciously 6 wrongful acts. Treble damages therefore amount to $1,191,225.00. 7 21. The Court may award reasonable attorney fees to the prevailing party in 8 exceptional cases. 35 U.S.C. § 285. 9 22. An exceptional case is one that “stands out from others with respect to the 10 substantive strength of a party’s litigating position (considering both the governing law and the 11 facts of the case) or the unreasonable manner in which the case was litigated.” Octane Fitness, 12 LLC v. ICON Health & Fitness, Inc., 572 U.S. 545 (2014). The court should consider the totality 13 of the circumstances and the prevailing party must show entitlement to an award by a 14 preponderance of the evidence. 15 23. This is an exceptional case meriting an award of attorney’s fees. Defendants 16 admitted to infringing Dr. Aoki’s patents early on in this case. The subsequent downstream 17 licenses even explicitly reference Dr. Aoki’s patents and Dr. Aoki’s technology as the source of 18 the APT technology. Defendants’ subsequent reversal of position that APT is not MAT is not 19 credible. And Defendants’ refusal to produce any financial documents also support a finding of 20 exceptional circumstances. Reasonable attorney’s fees will be awarded. 21 24. The Court may grant an injunction “in accordance with the principles of equity to 22 prevent the violation of any right secured by patent, on such terms as the court deems 23 reasonable.” 35 U.S.C. § 283. 24 25. “According to well-established principles of equity, a plaintiff seeking a 25 permanent injunction must satisfy a four-factor test before a court may grant such relief. A 26 plaintiff must demonstrate: (1) that it has suffered an irreparable injury; (2) that remedies 27 available at law, such as monetary damages, are inadequate to compensate for that injury; (3) that, 28 considering the balance of hardships between the plaintiff and defendant, a remedy in equity is 1 warranted; and (4) that the public interest would not be disserved by a permanent injunction.” 2 eBay Inc. v. MercExchange, L.L.C., 547 U.S. 388, 391 (2006). 3 26. “A plaintiff's past willingness to license its patent is not sufficient per se to 4 establish lack of irreparable harm if a new infringer were licensed. See eBay, 547 U.S. at 393, 5 126 S.Ct. 1837 (rejecting the district court's conclusion that ‘a plaintiff's willingness to license its 6 patents and its lack of commercial activity in practicing the patents would be sufficient to 7 establish that the patent holder would not suffer irreparable harm if an injunction did not issue’).” 8 Acumed LLC v. Stryker Corp., 551 F.3d 1323, 1328 (Fed. Cir. 2008). 9 27. Plaintiffs have demonstrated their entitlement to a permanent injunction. 10 Defendants’ use of Dr. Aoki’s MAT treatment under the guise of a different name has caused 11 irreparable injury to Dr. Aoki and ADRI for which monetary damages are insufficient. Dr. Aoki 12 is the inventor of the MAT treatment, for which he spent his entire career developing. The Court 13 has found there is no substantial distinction between APT and MAT, and that patients and 14 investors were lulled into falsely believing that APT was invented by Mr. Gilbert. A lack of 15 proper oversight led to clinics modifying the treatment in some instances, creating a “wild west of 16 medicine” and resulting in adverse consequences to patients. (See RT Vol. 16 at 2625:15–21.) 17 Absent an injunction, these practices will likely continue, and Plaintiffs will likely continue to 18 suffer irreparable harm (at a minimum to their name, reputation, and goodwill) for which 19 royalties from a license would not compensate. 20 28. The balance of hardships inquiry oftentimes compares the relative size of the 21 parties and their revenue sources in assessing the effect of granting or denying an injunction. See 22 i4i Ltd., 598 F.3d at 862. In this case, the record overall reflects that the subject technology is at 23 the heart of both Dr. Aoki and Mr. Gilbert’s enterprises. An injunction would no doubt largely 24 impact Mr. Gilbert and Trina Health to the extent any active clinics would cease to operate. 25 Nonethless, the Court finds the hardships tip in favor of Dr. Aoki. MAT is the result of Dr. 26 Aoki’s life’s work. The Trina clinics, by practicing what they purport to be APT, essentially 27 compete with Dr. Aoki’s MAT treatment by using that treatment and intentionally conflating it or 28 calling it their own. While an injunction is not an automatic result of a patent infringement, the 1 Court finds Dr. Aoki is entitled to possess the right to exclude others from using his property. 2 29. The Court has carefully considered the public interest in this matter. One thing the 3 parties seem to agree on is the fact that the treatment generally benefits patients. Nonetheless, the 4 evidence reflects that a lack of oversight at the clinics licensed by Trina Health resulted in 5 negative patient outcomes in some cases, indicating the public would be better served by the grant 6 of an injunction to halt operations of illegitimately licensed clinics. 7 Copyright Infringement Remedies 8 30. The Copyright Act authorizes an award of actual damages plus any profits 9 attributable to the infringement not taken into account in calculating the actual damages to the 10 plaintiff. 17 U.S.C. § 504(b). Alternatively, the copyright owner may elect to recover an award 11 of statutory damages, as Plaintiffs here have done. Id. at § 504(c)(1). 12 31. The Act provides for statutory damages of up to $30,000 per infringed work. Id. 13 Where the copyright owner proves infringement was willful, the Act authorizes enhanced 14 statutory damages of up to $150,000 per infringed work. Id. §504(c)(2). Willfulness may be 15 found where the defendant’s infringing actions are undertaken either with knowledge that the 16 conduct constitutes infringement or with reckless disregard for the copyright owner’s rights. See 17 In re Barboza, 545 F.3d 702, 707–08 (9th Cir. 2008). The court has broad discretion to determine 18 the amount of statutory damages. Peer Intern. Corp. v. Pausa Records, Inc., 909 F.2d 1332, 1336 19 (9th Cir. 1990). 20 32. The evidence demonstrates that this is not a situation of isolated, innocent 21 instances of infringement, but multiple instances of willful unauthorized uses. Even after this 22 lawsuit was filed in 2011, Defendants continued to use Dr. Aoki’s copyrighted slides in 23 promoting APT. Most glaringly, they used the foot wound photos of Dr. Aoki’s patient whom he 24 treated with MAT and which photos he copyrighted, to claim that the patient was treated with 25 APT rather than MAT. These facts demonstrate Defendants knew their conduct was unlawful or 26 at minimum engaged in reckless conduct sufficient to support a finding of willfulness. As such, 27 the maximum statutory damages for willful infringement is appropriate. 28 33. The Copyright Act authorizes a permanent injunction to prevent future 1 infringement where plaintiff has demonstrated: “(1) that it has suffered an irreparable injury; (2) 2 that remedies available at law, such as monetary damages, are inadequate to compensate for that 3 injury; (3) that, considering the balance of hardships between the plaintiff and defendant, a 4 remedy in equity is warranted; and (4) that the public interest would not be disserved by a 5 permanent injunction.” 17 U.S.C. § 502(a); see also, eBay Inc., 547 U.S. at 391–92. 6 34. For the same reasons discussed above in the context of patent infringement, the 7 Court finds Plaintiffs have suffered an irreparable injury as a result of infringement of the 8 protected copyright and that monetary damages provide inadequate compensation. Indeed, the 9 copyright infringement demonstrated by Plaintiffs goes hand-in-hand with the infringement of Dr. 10 Aoki’s patents. Dr. Aoki’s copyrighted slide deck represents the results of years of studies 11 concerning MAT, and Defendants use of the slides for promotion of APT deceived investors and 12 patients. Continued use is likely to have the same result, also indicating the public interest favors 13 an injunction. The balance of hardships tips in favor of Plaintiffs as there is no potential harm to 14 Defendants if they are forced to cease use of copyrighted materials to which they have no right. 15 35. The Copyright Act permits the court to award full costs and reasonable attorney’s 16 fees. 17 U.S.C. § 505. 17 36. A court may not award attorney's fees as a matter of course, but rather, must make 18 a more particularized, case-by-case assessment. Fogerty v. Fantasy, Inc., 510 U.S. 517, 533 19 (1994). 20 37. Objective reasonableness is an important but not controlling factor in assessing 21 whether to award fees. “Although objective reasonableness carries significant weight, courts 22 must view all the circumstances of a case on their own terms, in light of the Copyright Act's 23 essential goals.” Kirtsaeng v. John Wiley & Sons, Inc., 136 S. Ct. 1979, 1989 (2016). 24 38. As stated above, the record demonstrates Mr. Gilbert, Bionica, and Trina Health 25 have willfully infringed the copyright at issue here and continued to do so even after this action 26 was filed. Moreover, even if Defendants were able to put forth a reasonable defense of fair use of 27 the slides in another (hypothetical) context, Defendants’ specific use of the slides as 28 representative of APT is egregious and such repeated infringement should be deterred. See id. 1 Reasonable attorney’s fees and full costs are warranted. 2 Lanham Act Remedies 3 39. A plaintiff who establishes a violation of § 43(a) of the Lanham Act is entitled to 4 recover, “(1) defendant’s profits, (2) any damages sustained by the plaintiff, and (3) the costs of 5 the action. . . . In assessing profits, the plaintiff shall be required to prove defendant’s sales only; 6 defendant must prove all elements of cost or deduction claimed.” 15 U.S.C. §1117(a) (emphasis 7 added). 8 40. “In assessing damages the court may enter judgment, according to the 9 circumstances of the case, for any sum above the amount found as actual damages, not exceeding 10 three times such amount. If the court shall find that the amount of the recovery based on profits is 11 either inadequate or excessive the court may in its discretion enter judgment for such sum as the 12 court shall find to be just, according to the circumstances of the case. Such sum in either of the 13 above circumstances shall constitute compensation and not a penalty.” Id. 14 41. “The district court assesses any damages sustained by the plaintiff in the same 15 manner as in tort damages: the reasonably foreseeable harms caused by the wrong.” Skydive 16 Arizona, Inc., 673 F.3d at 1112. 17 42. An exact amount of actual damages need not be proven. In measuring harm to 18 goodwill, a jury may consider a plaintiff's expenditures in building its reputation in order to 19 estimate the harm to its reputation after a defendant's bad acts. Id. 20 43. As discussed above with respect to FAL liability, Plaintiffs have failed to 21 adequately demonstrate any actual damages caused by Defendants’ false or misleading 22 advertising. Indeed, even Plaintiffs’ presumed loss of goodwill is not tied to any economic harm. 23 Plaintiffs seem to concede this in their proposed conclusions of law. (ECF No. 430 at 70.) 24 44. Nonetheless, and despite Defendants’ refusal to produce financial statements, 25 Plaintiffs have demonstrated Defendants Gilbert, Trina Health, and Bionica profited at least 26 $5,626,500 in chair license fees, training fees, and oversight fees and $2,310,000 in pump sales 27 stemming from their false advertising. No Defendant proffered evidence of cost or other 28 deduction to offset this amount. 1 45. Treble damages are not appropriate on Defendants’ profits, as distinguished from 2 Plaintiffs’ damages. See Bowmar Instrument Corp. v. Continental Microsystems, Inc., 497 F. 3 Supp. 947, 961 (S.D.N.Y. 1980). Nor do the circumstances of this case indicate an award in the 4 amount of Defendants’ estimated profits is inadequate compensation where, as here, the award is 5 not intended to be punitive. 6 46. Plaintiffs are entitled to costs as “one of the routine elements of a prevailing 7 plaintiff’s recovery” under the Lanham Act. Bowmar Instrument Corp. v. Continental 8 Microsystems, Inc., 497 F. Supp. 947, 961 (S.D.N.Y. 1980). 9 47. Under 15 U.S.C. § 116, courts may grant injunctions to prevent violations of § 10 43(a) of the Lanham Act. For the same reasons set forth above with respect to copyright 11 infringement, Plaintiffs are entitled to a permanent injunction under the Lanham Act as well. 12 48. “The court in exceptional cases may award reasonable attorney fees to the 13 prevailing party.” 15 U.S.C. § 1117(a). 14 49. The court’s analysis of the fee shifting provision of the Lanham Act mirrors that of 15 the Patent Act. See SunEarth, Inc. v. Sun Earth Solar Power Co., Ltd., 839 F.3d 1179, 1180 (9th 16 Cir. 2016). “Therefore, district courts analyzing a request for fees under the Lanham Act should 17 examine the ‘totality of the circumstances’ to determine if the case was exceptional, Octane 18 Fitness, 134 S.Ct. at 1756, exercising equitable discretion in light of the nonexclusive factors 19 identified in Octane Fitness and Fogerty, and using a preponderance of the evidence standard.” 20 Id. at 1181. 21 50. For the reasons set forth above, then, Plaintiffs are again entitled to reasonable 22 attorney’s fees. 23 Breach of Fiduciary Duty and Confidentiality Remedies (as to Mr. Gilbert only) 24 51. “Recovery for damages based upon breach of fiduciary duty is controlled by Civil 25 Code [§] 3333, the traditional tort recovery.” Michelson v. Hamada, 29 Cal. App. 4th 1566, 1582 26 (1994). 27 52. “Where a person profits from transactions conducted by him as a fiduciary, the 28 proper measure of damages is full disgorgement of any secret profit made by the fiduciary 1 regardless of whether the principal suffers any damage.” Am. Master Lease LLC v. Idanta 2 Partners, Ltd., 225 Cal. App. 4th 1451, 1483 (2014) (internal citations omitted). 3 53. “Where a benefit has been received by the defendant but the plaintiff has not 4 suffered a corresponding loss or, in some cases, any loss, but nevertheless the enrichment of the 5 defendant would be unjust . . . the defendant may be under a duty to give to the plaintiff the 6 amount by which [the defendant] has been enriched.” Id. at 1482 (internal citations omitted). 7 54. “In measuring the amount of the defendant's unjust enrichment, the plaintiff may 8 present evidence of the total or gross amount of the benefit, or a reasonable approximation 9 thereof, and then the defendant may present evidence of costs, expenses, and other deductions to 10 show the actual or net benefit the defendant received.” Id. at 1487. 11 55. Plaintiffs have not put on evidence of separate damages to which they may be 12 entitled as a result of Mr. Gilbert’s breach of confidentiality. 13 56. Nonetheless, the Court finds Plaintiffs are entitled to disgorgement of Mr. 14 Gilbert’s profits, which Plaintiffs have reasonably established to be a total of $7,936,500 from 15 chair fees, oversight fees, training fees, and pump sales for the 33 established Trina clinics. 16 Defendant has proffered no evidence of costs, expenses, or deductions. 17 57. Punitive damages are appropriate for a breach of fiduciary duty. Michelson, 29 18 Cal.App.4th at 1582. Under California Civil Code § 3294, punitive damages may be recovered 19 where “oppression, fraud, or malice” is proven by clear and convincing evidence. 20 58. “The purpose in awarding punitive damages is to punish wrongdoers and thereby 21 deter the commission of wrongful acts. An award should be no larger than the amount necessary 22 to accomplish this purpose and therefore must be tailored to the defendant's financial status. . . . 23 Factors to be considered include the nature of the acts of the defendant and the wealth of the 24 defendant.” Michelson, 29 Cal. App. 4th at 1593 (1994) (internal citations omitted). 25 59. “Three factors guide determination of punitive damages under California law: (1) 26 the nature of the defendants' acts; (2) the amount of compensatory damages awarded; and (3) the 27 wealth of the defendant. . . . The plaintiff carries the burden of producing evidence of a 28 defendant’s financial condition.” Nat'l Integrated Techs., Inc. v. Gustavson, 76 F. App'x 774, 778 1 (9th Cir. 2003) (internal citation omitted). 2 60. There is no evidence in the record even hinting at Mr. Gilbert’s financial 3 condition. The Court is aware that this void was caused at least in part by Defendant’s refusal to 4 comply with discovery requests and court orders, but the fact remains that the Court cannot 5 fashion a punitive damages award based solely on speculation. See id. at 779. As a result, the 6 Court awards no punitive damages. 7 Affirmative Defenses 8 61. To the extent Defendants assert affirmative defenses aside from the patent 9 invalidity addressed above, those defenses were not raised in trial or in post-trial briefing and 10 Defendants have therefore not met their burden concerning any pleaded affirmative defense. 11 IV. CONCLUSION 12 Based on the foregoing findings of fact and conclusions of law, the Court concludes 13 Defendants Gregory Ford Gilbert, Bionica Inc., and Trina Health, LLC, are jointly and severally 14 liable for patent infringement, copyright infringement, and false and misleading advertising and 15 unfair competition under federal law. Additionally, Defendant Gilbert is liable for breach of 16 fiduciary duty and breach of confidentiality. Judgement shall be entered in favor of Plaintiffs on 17 those claims. The Court finds the same Defendants are not liable under California’s FAL or 18 UCL. 19 Plaintiffs have proven entitlement to damages amounting to $7,936,500, plus statutory 20 damages of $150,000. Plaintiffs are also entitled to reasonable attorney’s fees, costs, and 21 injunctive relief. 22 Not later than thirty (30) days from the date of electronic filing of this order, Plaintiffs are 23 ordered to file the following: (1) a proposed order setting forth the terms of permanent injunction, 24 including the scope and effective date of injunctive relief; and (2) a motion for attorney’s fees. 25 IT IS SO ORDERED. 26 DATED: November 16, 2020 27 28